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The clinical state of high risk of psychosis defines a condition
characterised by attenuated psychotic symptoms, brief limited
intermittent psychotic episode, genetic vulnerability or the
presence of basic symptoms.1 As the name suggests, these
diagnostic criteria were originally developed to identify people
at high risk of developing a psychotic disorder over time. Under
this conceptualisation the condition would allow detection and
treatment of a group at very high risk of developing a severe
and full disorder longitudinally. This paradigm would fit the aims
of indicated prevention in this group,2 who have up to 30% risk of
developing psychosis, mostly schizophrenia spectrum disorders,3
within the following 2 years. Accordingly, preventive treatments
primarily aim at reducing the risk associated with the condition
and thus preventing the outcome.4,5 The ‘high risk’ paradigm does
not explicitly require functional impairments as inclusion
criteria,6 with the exception of the genetic risk and deterioration
subgroup, which however is traditionally small. On the other
hand, over the past few years a competing paradigm has emerged.
The ‘attenuated psychosis’ syndrome (APS) has been published in
DSM-5.7,8 The APS construct specifically requires patient distress
or disability, which has not explicitly been part of the high-risk
concept, although distress and disability are implicit in the
symptom severity ratings that are required for the research
diagnosis of high risk,8 defined as ultra-high risk (so not basic
symptoms). In this sense the APS better resembles the clinical
condition of angina pectoris, which is per se associated with signs
and symptoms impairing the quality of life (QoL) and level of
functioning of the individual. The APS diagnosis has been
relegated to the research appendix of the DSM-5 because of lack
of consensus among researchers on the validity of this category
as a syndrome and for the inconclusiveness of data supporting
its diagnostic reliability.9
One way to partially circumvent this controversial issue is to
clarify the functional status of people at high risk at the time of
their presentation to prodromal services and independently from
their longitudinal outcomes. In fact, according to the DSM
criteria,7 an impairment of functioning along with significant
distress are basic criteria for the conceptual validity of all
psychiatric disorders,10 differentiating a physiological trait or
asymptomatic risk factor from a disorder and determining the
patient’s need for treatment: ‘mental disorders are usually
associated with significant distress in social, occupational, or other
important activities’.7 A number of studies investigating
functioning or QoL in people at high risk have been published
in recent years. Surprisingly, to date no quantitative synthesis
has been published regarding the functioning and QoL of such
people when they are seeking help from prodromal clinics. The
results are particularly controversial when people at high risk are
compared with patients with established psychosis.11–14
Our first aim was to investigate validity of the high-risk state
by addressing consistency and magnitude of baseline functioning
and QoL in high-risk individuals compared with a healthy
control group and people with a frank diagnosis of psychosis.
We additionally investigated the impact of baseline difference in
high-risk functioning on the longitudinal development of psychotic
disorders.
Method
The main research hypothesis and the study protocol were decided
a priori. We used a systematic search strategy to identify relevant
articles. Two investigators (A.S. and A.A.) conducted a two-step
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Background
The nosology of the psychosis high-risk state is controversial.
Traditionally conceived as an ‘at risk’ state for the
development of psychotic disorders, it is also conceptualised
as a clinical syndrome associated with functional impairment.
Aims
To investigate meta-analytically the functional status of
patients at high clinical risk for psychosis and its association
with longitudinal outcomes.
Method
Three meta-analyses compared level of functioning (n=3012)
and quality of life (QoL) (n=945) between a high-risk group, a
healthy control group and group with psychosis, and baseline
functioning in people in the high-risk group who did or did
not have a transition to psychosis at follow-up (n=654).
Results
People at high risk had a large impairment in functioning
(P<0.001) and worse QoL (P=0.001) than the healthy control
group, but only small to moderately better functioning
(P=0.012) and similar QoL (P=0.958) compared with the
psychosis group. Among the high-risk group, those who did
not develop psychosis reported better functioning (P=0.001)
than those who did.
Conclusions
Our results indicate that the high-risk state is characterised
by consistent and large impairments of functioning and
reduction in QoL similar to those in other coded psychiatric
disorders.
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literature search. As a first step the Web of Knowledge database
(Thomson Reuters) was searched, incorporating both the Web
of Science and Medline. The search was extended until December
2013, including abstracts in English language only. The electronic
research adopted several combinations of the following keywords:
‘‘at risk mental state’’, ‘‘psychosis risk’’, ‘‘prodrome’’, ‘‘prodromal
psychosis’’, ‘‘ultra high risk’’, ‘‘functioning’’, ‘‘quality of life’’ and
name of the possible assessment instruments (see online
supplement DS1 for details). The second step involved the
implementation of an additional electronic search based on a
manual search of the reference lists of the retrieved articles.
Abstracts of articles identified through these two steps were then
screened for the selection criteria, and articles surviving this
screening were assessed for eligibility on the basis of a full-text
reading. Discrepancies were resolved through consensus with
a third author (M.R.). To achieve a high standard of reporting
we adopted the Meta-analysis of Observational Studies in
Epidemiology (MOOSE) checklist.15
Selection criteria
Inclusion criteria for the first two meta-analyses, focusing on the
difference between the groups in functioning (meta-analysis 1)
and QoL (meta-analysis 2), were as follows:
(a) original article, written in English;
(b) inclusion of a sample at high risk (i.e. presence of attenuated
psychosis symptoms, genetic risk and deterioration, brief
limited and intermittent psychotic episode, basic symptoms)
according to international standard definition;1
(c) inclusion of a comparison group of healthy participants or
patients with psychosis;
(d) cross-sectional study, cohort study or descriptive study
reporting sufficient meta-analytical data on functioning.
Meta-analysis 3 focused on the difference in functioning
between high-risk participants who made (HR-T) or did not make
(HR-NT) a transition to psychosis at follow-up in descriptive
longitudinal studies. Inclusion criteria (a) and (b) were the same
as above, with an additional criterion that the article reported
baseline data on functioning together with the longitudinal
transition outcome at follow-up. Exclusion criteria were common
to all analyses: articles were excluded if they were abstracts, pilot
data-sets or reviews, failed to report enough data for meta-analysis
or had overlapping data-sets. Specifically, in case of multiple
publications deriving from the same study population, we selected
the article reporting the largest and most recent data-set.
Recorded variables
Data extraction and quality assessment were independently
performed by two investigators (A.S. and A.A.). Inconsistency and
disagreements on quality rating were double-checked and resolved
with a third author (M.R.). The following variables were recorded
from each article: author, year of publication, quality criterion (see
below), comparison group type (healthy participants or patients
with established psychosis), epidemiological data of high-risk
and control samples (baseline sample sizes, mean age, proportion
of females), the high-risk diagnostic instrument adopted, the
instrument employed to assess functioning and the level of
functioning. The last variable was the primary outcome measure
for the first meta-analysis. The following data on functioning were
extracted: mean value and standard deviation of the mean in both
the high-risk and comparison groups, direction of the difference
and level of significance of the difference.16 We additionally
extracted data on QoL as defined by the mean of different psycho-
metric instruments and used it as secondary outcome measure. If
the data were reported for subgroups we merged the values
(online Table DS1). For meta-analysis 3 we extracted baseline
functioning in the HR-T and HR-NT groups as the primary
outcome. Demographic data, publication year and duration of
follow-up (months) were extracted finally to assess their putative
moderator effect.
Quality assessment
Although quality assessments can be reliably conducted in meta-
analyses of experimental studies their use in observational research
is controversial, with no clear consensus on rating methods or their
appropriate use in the analysis.17 We adapted the Newcastle–
Ottawa Scale for the evaluation of non-randomised studies (www.
ohri.ca/programs/clinical_epidemiology/oxford.asp). The scale
evaluates the quality of observational studies, allocating a maximum
of nine stars for the highest quality. This tool has been adopted in
recent meta-analyses.18
Statistical analysis
We performed three meta-analyses using Comprehensive Meta-
Analysis Software version 2.19 When the same outcome was
evaluated within the same study with more than one scale we
retained just one measure according to a predefined order (see
Method in online supplement DS1). As a measure of effect size
in meta-analyses 1 and 2 Hedges’ g was adopted, i.e. the difference
between the functioning (or QoL) means of the comparison and
high-risk groups, divided by the standard deviation and weighted
for sample size, to correct for bias from small sample sizes. In
meta-analysis 3 Hedges’ g was employed to test differences in
functioning between the HR-T and HR-NT groups. The influence
of putative continuousmoderators (year of publication, demographic
variables, length of follow-up) was tested using meta-regression
analyses, dividing the significance level (P= 0.05, two-tailed) by
number of moderators tested to adjust for multiple comparisons.
The slope of meta-regression line – b coefficient: direct (+) or
inverse (7) – indicates the strength of the relationship between
moderator and outcome. Meta-regressions were performed when
at least ten studies were available for the preselected outcome of
interest. We additionally performed a supplementary analysis
using the cross-sectional studies employing the Global Assessment
of Functioning (GAF). Furthermore, since the most recent studies
adopting the Comprehensive Assessment of At-Risk Mental States
(CAARMS) for high-risk state included functioning as a
diagnostic criterion,9 a subgroup analysis was performed to
control for this possible confounder. Further methodological
details are available in online supplement DS1.
Heterogeneity, publication bias and sensitivity
Heterogeneity among study point estimates was assessed using Q
statistics,20 with the proportion of the total variability in the effect
size estimates being evaluated with the I2 index.21 As meta-analysis
of observational studies is supposed to be characterised by
significant heterogeneity, random effect models were used. In
general, random effect models are more conservative than fixed
effect models, and appear to better address heterogeneity between
studies and study populations, allowing for greater flexibility in
parsing effect size variability. Moreover, they are less influenced
by extreme variations in sample size.22 The possibility of a
publication bias in our study was tested with the Duval & Tweedie
trim and fill method.23 This method imputes values estimated
to be missing from the analysis (e.g. for publication bias) and
re-estimates the effect size. If the conclusion of the meta-analysis
remains unchanged following the trim and fill adjustment the
results can be considered as robust. To further assess the robustness
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of the results, we performed sensitivity analyses by sequentially
removing each study and rerunning all three meta-analyses. We
also conducted a second sensitivity analysis for meta-analysis 2
excluding studies with quality ratings in the lowest quartile, to
determine whether potential methodological weaknesses influenced
meta-analytic estimates.
Results
For meta-analyses 1 and 2 electronic and manual search
uncovered 1168 potential abstracts. After the first screening
through abstract reading 226 full-text articles were downloaded
for selection, of which 30 met the inclusion criteria as they were
comparing functioning or QoL between high-risk participants
and comparisons, accounting for a total of 3608 participants
(meta-analysis 1: n=3012, mean age 20.7 years, 38.8% female;
meta-analysis 2: n= 945, mean age 23.7 years, 41.4% female;
online Fig. DS1 (a) and (b)). There were no studies employing
basic symptom criteria in the final database. For meta-analysis
3, electronic and manual search uncovered 1181 potential
abstracts. After the first screening through abstract reading 244
full-text articles were downloaded for selection; of these, 10
longitudinal studies reporting baseline functioning in the transition
and non-transition groups were eventually included (mean length
of follow-up 28.3 months, n=654; mean age at baseline 19.1 years,
43.5% female; online Fig. DS1 (c)). The details of the final
database are reported in online Table DS2.
Functioning in high-risk individuals
Comparison with healthy control group
There was a large and significant impairment in functioning
across the high-risk group compared with the healthy control
group, with small 95% confidence intervals indicating the
precision of the estimate (Hedges’ g=73.01, 95% CI 73.68 to
72.34, P50.001, n= 18; Fig. 1(a)). The Duval & Tweedie trim
and fill procedures found no missing study (random model
applied), suggesting absence of publication bias. There was
considerable heterogeneity across the included studies
(Q= 497.4, I 2 = 96.6%, d.f. = 17, P50.001) but the direction of
the effect was consistent and significant for each study. No study
accounted for more than 5.9% of the overall effect size. Meta-
regression analysis adjusted for multiple comparison found that
a proportion of females in the healthy control group was
correlated with the magnitude of the effect size (b=72.61, 95%
CI73.75 to71.48, P50.001, Q= 20.5, n=15). Conversely, there
was no association between level of functioning and high-risk
gender, high-risk or healthy control group age or publication year.
The sensitivity analysis computing after removing each study and
the studies in the lower quartile of quality rating confirmed our
findings with no significant change.
Comparison with the psychosis group
People in the high-risk group were less impaired on functional
status than patients with frank psychosis. The magnitude of this
effect was small to moderate (Hedges’ g=0.34, 95% CI 0.07 to
0.60, P= 0.012, n= 14; Fig. 1(b)), with large confidence intervals
indicating imprecision. There was no publication bias. There was
significant heterogeneity across studies (Q=63.3, I 2 = 79.5%,
d.f. = 13, P50.001). Meta-regression analyses adjusted for
multiple comparisons revealed better functioning in women in
both high-risk (b=71.76, 95% CI 73.03 to 70.49, P= 0.007,
Q= 7.4, n= 14) and psychosis group (b=72.43, 95% CI 73.61
to 71.25, P50.001, Q= 16.3, n= 14) comparisons (online Fig.
DS2). Conversely, there was no association in either group with
age or with publication year. These results were confirmed by
sensitivity analyses. Results of the supplementary analyses
investigating the mean GAF scores of the three comparison
groups, and the possible effect of the high-risk diagnostic tool
(i.e. CAARMS v. Structured Interview for Prodromal Symptoms,
SIPS), are reported online (Figs DS3 and DS4).
Quality of life
Meta-analysis 2 showed that the high-risk group had poorer QoL
than the healthy control group (Hedges’ g=71.75, 95% CI72.83
to 70.67, P= 0.001, n=4; Fig. 2(a)). Furthermore, we found no
difference in QoL between the high-risk and psychosis groups
(Hedges’ g=0.02, 95% CI 70.64 to 0.67, P=0.958, n=3; Fig.
2(b)). The heterogeneity in the subgroup analysis was considerable
(high-risk v. healthy control group: Q= 91.8, I 2 = 96.7%, d.f. = 3,
P50.001; high-risk v. psychosis group: Q=16.1, I 2 = 87.6%,
d.f. = 2, P50.001); however, given the small number of studies,
we did not perform meta-regression analyses. The sensitivity
analysis computing after removing each study confirmed our
findings, with no significant change.
Functioning and psychosis transition
There was meta-analytical difference in baseline level of
functioning between the HR-T and HR-NT groups (mean
follow-up 28.9 months, s.d. = 16.0). The magnitude of the effect
was moderate, with those in the HR-T group showing poorer
baseline functioning than the HR-NT group (Hedges’ g= 0.43,
95% CI 0.17 to 0.68, P=0.001, n= 10; Fig. 3). The trim and fill
procedure showed that the result was robust against publication
bias. The heterogeneity between studies was moderate (Q=20.0,
I2 = 54.9%, d.f.= 9, P=0.018).Meta-regressions adjusted formultiple
comparisons revealed a significant correlation with publication
year (b=70.10, 95% CI 70.17 to 70.03, P=0.005, Q= 7.8,
n= 10), but no association with length of follow-up (P= 0.121),
gender of participants (P=0.651) or age (P=0.254). The sensitivity
analysis computing after removing each study confirmed our
findings with no significant change.
Discussion
People at high risk of psychosis (defined on the basis of ultra-high
risk criteria) had a statistically significant impairment in global
functioning that was very large compared with a healthy control
group, but only small to moderate when compared with patients
with psychosis. Within the high-risk group, lower baseline level of
global functioning predicted the later onset of psychosis. Impair-
ments of QoL in the high-risk group were similar to those
observed in the psychosis group. The results were robust and not
affected by publication bias.
The results of our meta-analysis are important for research
and clinicians working in the field of psychosis prevention because
there is no consensus with respect to the functional status of
people at high risk of psychosis. For example, some authors argue
that such people are not at all dysfunctional, as their signs and
symptoms represent ‘normal developmental processes’ or
expressions of psychosis vulnerability that are common in the
general population.24 These authors also suggested that help-
seeking is only a behaviour not suggestive of functional
impairments and questioned whether these individuals actually
need treatment,24 concluding that ‘it is not appropriate to treat
high-risk people before the psychosis onset’.25 To our knowledge
this is the first ever meta-analysis clearly addressing these
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speculations and investigating the functional status of high-risk
participants compared with healthy control and psychosis groups.
Functional impairment
We clearly found that functioning of people at high risk was
strongly impaired compared with the healthy control group but
only modestly impaired compared with people with psychosis.
These impairments may have been present for a long period prior
to referral to high-risk services.26 Our supplementary analysis
focusing only on studies employing the GAF indicated a mean
score of about 79 for the healthy control group, 50 for the high-
risk group and 45 for the psychosis group. This pattern suggests
that the functional level in people at high risk is closer to that
observed in people with psychosis as opposed to that observed
in healthy individuals. This pattern is further supported by the
meta-analysis of the QoL, which found no significant difference
between the high-risk and psychosis groups and again a significant
reduction in QoL compared with the healthy control group. It is
relevant that functional impairment as well as QoL reported for
the high-risk group was observed at the initial assessment in early
detection centres before any focused intervention was initiated.
Impairments in functioning and QoL are therefore a key feature
of the high-risk state, at least as defined with the ultra-high risk
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Fig. 1 Functional impairment: forest plots of meta-analysis 1. The large effect size of the subgroup analysis indicated (a) lower
functioning of the high-risk group v. the healthy control group and (b) a moderate standardised difference in functioning between the
high-risk group and the psychosis group.
GAF, Global Assessment of Functioning; GF-social, Global Functioning – social scale; HR, high risk; SOFAS, Social and Occupational Functioning Assessment Scale; SFS, Social
Functioning Scale.
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criteria (we found no basic symptom studies eligible for the
current meta-analysis). Since QoL in the high-risk group was
similar to that observed in patients with psychosis, it is possible
to argue that severe functional impairment may lead to self-
stigmatising by high-risk patients independently of any diagnostic
label.27 To better understand the magnitude of the functional
impairment of the high-risk state, it can be qualitatively compared
with that of other psychiatric disorders (Fig. 4).
Although such a comparison should be interpreted cautiously
as it is not based on original data, on a qualitative basis the graph
indicates that the point estimate of the global functioning in the
high-risk group is lower than those observed in bipolar disorder,
and similar to that of major depressive disorders and social phobia.
This is the first meta-analytical evidence that high-risk individuals
are ‘probably at risk but certainly ill’, as previously advocated.28
The findings of large functional impairments in the high-risk
group clearly contradict the speculative assumption that they
represent normal developmental phenotypes and are not in need
of care. Conversely, in synopsis of the results of the meta-analyses
and the qualitative placement of the observed GAF scores shown
in Fig. 4, it seems strongly justifiable to conclude that the
functional state observed in those meeting high-risk criteria calls
not only for prevention of a future transition to psychosis, but also
for treatment of the current mental state and problems.
Comorbidity
It may be argued that functional impairment in those at high risk
of psychosis is secondary to comorbid disorders diagnosed in this
group. There is evidence that affective comorbidities are highly
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Fig. 3 Baseline functional impairment and transition to psychosis: forest plot of meta-analysis 3. Participants at high risk who developed
psychosis during the follow-up period had poorer baseline functioning than participants who did not.
GAF, Global Assessment of Functioning; HR-NT, high risk, no transition to psychosis; HR-T, high risk, transition to psychosis; SOFAS, Social and Occupational Functioning Assessment
Scale.
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Fig. 2 Quality of life: forest plots of meta-analysis 2. The subgroup analysis indicated that quality of life of the high-risk group was worse
than that of the healthy control group (a) but similar to that of the psychosis group (b).
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prevalent in these individuals,29 affecting psychopathology,
neurobiology and baseline functioning.30,31 However, in an earlier
meta-analysis we found comorbid affective disorders to be present
in less than half of the high-risk group (comorbid depressive
disorder 41%, anxiety disorder 15%).30 Consequently, the
functional and QoL impairment observed in the high-risk group
could not entirely be secondary to the presence of affective
comorbidities. The European Prediction of Psychosis (EPOS)
study estimated the impact of both high-risk and depressive
psychopathology on baseline GAF scores, using the Beck
Depression Inventory and the SIPS as independent variables; step-
wise linear regression retained SIPS-positive and SIPS-negative
scores only, explaining 14.9% of variance and thus indicating
that GAF scores were predominantly determined by deterioration
of role functioning.32 On the other hand, even if comorbid
symptoms fulfilling the thresholds for certain DSM or ICD
disorders had an impact on the GAF ratings, these scores could
be interpreted as a true expression of the high-risk state: such
comorbid symptoms could well be considered as part of the
high-risk state, in line with retrospective findings indicating
that prevalence of depressive mood at the time of psychosis
onset is 83%,33 and with phenomenological evidence of affective
dysregulation at the core of psychosis liability.34 Affective
symptoms may thus be part of the high-risk state and might be
expression of an early, mild stage of the same neurobiological
process that causes psychosis.33
Specificity and sensitivity
We also supported the notion that functional impairment may
help in enriching the risk (specificity) of high-risk samples.35 In
fact, as compared with ultra-high-risk individuals,36 short-term
transition risk in individuals with psychotic-like symptoms but
good functioning is extremely low (about 1.2% within 2 years).37
However, it is possible that rigorous functioning criteria might
enrich the high-risk sample but at the cost of sensitivity. Another
study investigating the prevalence of high-risk symptoms in a
community sample aged 11–13 years found the proportion of
participants meeting CAARMS high-risk criteria declined from
7.7% to 0.9% when a 30% decrease of functioning was considered
a criterion.38 Thus, at least at the population level, adding this
functioning criterion may lead to an immense loss of sensitivity.
A corresponding finding was reported from the Personal Assess-
ment and Crisis Evaluation (PACE) 400 study.39 It has still to be
elucidated in longitudinal follow-up studies whether there is a
criterion leading to a better balance of sensitivity and specificity;
however, risk stratification might overcome this problem.32
Furthermore, even without transition to psychosis, functional
decline may constitute an outcome of the high-risk state with a
comparable clinical significance. Thus, besides a loss of sensitivity,
defining impaired functioning as an obligatory entry criterion for
high-risk status may result in missing the main goal of prevention,
i.e. lowering the huge personal and socioeconomic burden of the
disease related to impaired functioning.40 Future studies may
therefore have to find a balance between sufficient risk enrichment
in terms of transition to psychosis and sufficient sensitivity in
terms of functional outcome.
The need for care
Besides these speculations, our meta-analysis provides conclusive
and consistent evidence that people at high risk are truly in need
of care. Our analysis found no evidence of publication bias, and all
the sensitivity analyses performed confirmed our findings. We
investigated factors modulating functional level in high-risk
participants. A small proportion of the observed heterogeneity
was explained by gender, suggesting better functional level in
women with psychosis. Such a result is in line with available
studies in the psychosis spectrum disorders reporting higher
functional levels in women than in men.41
Our longitudinal meta-analysis revealed that high-risk
individuals who later developed psychosis had poorer functioning
at baseline. This finding is not new,42 and is in line with the
significant predictive value of high-risk functional impairment
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Fig. 4 Qualitative comparison of Global Assessment of Functioning (GAF) scores in different psychiatric conditions.
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towards transition that has been reported in large independent
samples.32,43–45 Some authors support the idea of high risk as a
continuum towards psychosis, marked by a change in functioning
and course of thinking.43 These results may have both clinical and
research implications. High-risk samples could be stratified at
baseline on the basis of their functional level and focused inter-
ventions or experimental trials could be individualised
accordingly. Additionally, since most high-risk participants
received at least in part some active treatment, our longitudinal
results are in line with reports of low efficacy of preventive
interventions on social functioning in these people.5 In this
analysis we found a significant modulating effect for year of
publication, suggesting that in the most recent studies the
difference in functioning between the two transition groups
decreased. This can be interpreted as the consequence of changes
in recruitment strategies of prodromal clinics, with inclusion of
less functionally impaired patients in the most recent years.1
Overall, when interpreting the impact of baseline functioning on
transition outcomes, it is important to note that psychosis is just
one possible outcome of the high-risk state; remission, transition
to a non-psychotic disorder and persistence of the high-risk state
account for the majority of outcomes at follow-up.1 Our analysis
was unable to test the impact of baseline level of functioning on
these outcomes. Functional status, on the other hand, could be
considered as a good indicator of broader clinical outcome also
in patients who will subsequently develop psychosis.1,35
Study limitations
Some limitations need to be acknowledged. First, the concept of
functional impairment had some intrinsic conceptual caveats.
Most of the scales adopted, especially the GAF, do not provide a
clear distinction between functioning and symptoms.46 However,
the vast majority of studies of the high-risk state published to date
have used the GAF as a standard measure of functioning. The
Social and Occupational Functioning Assessment Scale (SOFAS)
has been developed to overcome this issue. Unlike the GAF, which
includes not only social and occupational performance but also
symptoms as a dimension of functioning, the SOFAS aims to
assess functioning without the influence of the patient’s
symptoms.47 However, both scales have strong negative
correlations with the Clinical Global Impression and the Positive
and Negative Syndrome Scale.47 Further development in the field
may imply the use of psychometric instruments powered to
disentangle these two overlapping domains. Another limitation
is that we did not attempt to acquire unpublished data. Yet
another is that in both subgroup analyses a large part of the
heterogeneity remained unexplained. Differences in sampling
procedures and assessment measures could be some of the
putative moderators that further studies need to take into account
to increase the generalisability of findings. Also, the quality of the
studies included may have affected interpretation of the results:
only half of the studies used a matched (i.e. at least by age)
comparison group (see online Table DS3). Another potential
limitation is that the researchers assessing functioning and QoL
were masked to case–comparison allocation in only a minority
of studies. However, our sensitivity analysis showed no effect of
quality of studies on the meta-analytical estimates. Furthermore,
given conceptual and pragmatic differences between the high-risk
and DSM-5 paradigms,6 and given the lack of generalisability of
high-risk research to the general population,48 our findings cannot
be directly used to support the validity of the APS diagnosis. Our
results support conceptual validity of the high-risk state, i.e.
correctly distinguishing between disorder and normality,49 rather
than its construct validity. Conversely, DSM-5 criteria for a mental
disorder focus on construct validity, requiring that the disorder in
question is distinct from other disorders, has familial aggregation,
presence in diverse populations and environmental risk factors,
has concurrent validators such as cognitive and temperament
correlates, biological markers and a certain comorbidity profile,
and has predictive validity with respect to diagnostic stability,
predictability of the course of illness, and response to treatment.50
Conceptual and construct validity are independent.49 Although
the high-risk state may encompass different comorbid
disorders,30,31 and thus lack full construct validity, it can be
conceptually valid since it encompasses only disorders. However,
the same arguments can be used to question construct validity
of affective disorders, given their high co-occurrence during first
episodes of psychosis.33 Indeed, satisfying construct validity has
as yet not been achieved even for many other hitherto encoded
mental disorders. A full discussion of these issues is beyond the
scope of the current investigations and has been critically
presented in other recent papers.6,51
Clinical implications
The high-risk state (defined with ultra-high risk criteria) is
characterised by consistent and serious impairments of functioning
and reduction of QoL that seem to be similar to those in other
coded psychiatric disorders. These impairments call not only
for prevention of a future transition to psychosis and functional
deterioration, but also for treatment of the current disorder.
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Method 
Research code 
We adopted the following code for our multiple database electronic search: 
(("at risk mental state" OR "at-risk mental state" OR "psychosis risk" OR (prodrom* AND psycho*) OR ultra-high 
risk OR UHR OR CAARMS OR SIPS OR SOPS OR SPIA) AND ("functioning" OR GAF OR "Global Assessment 
of Functioning" OR quality of life OR *QOL* OR QLS))  
The keywords were searched in titles, abstracts, author keywords and with the Thomas Reuters tool Keywords 
Plus®. The electronic search retrieved 1156 studies. 
Data extraction 
For the data extraction we adopted the following a priori rules: 
- We classified “non-psychiatric controls” and “non HR subjects” and “subjects without psychiatric 
disorders” as “healthy controls”. 
- When more than one scale was adopted for the primary outcomes, we selected the first measure available in 
the following order: 
o Functioning: 
 GAF 1 
 SOFAS 1 
 GF social 2 
 Others 
o Quality of Life: 
 QLS 3 
 MSQoL 4 
 Others  
- Null hypothesis significance tests were considered two tailed if not otherwise specified. 
In Hui et al. 2013 5 the GAF scale 1 was divided into subscales. We excluded the symptoms subscale measure and 
included the disability subscale, accordingly with the topic of the study. 
Supplementary meta-analyses 
We performed a supplementary subgroup analysis to investigate the mean GAF scores in HR, healthy comparisons 
and patients diagnosed with psychosis. We decided to investigate this particular scale as it was recommended for 
global assessment of functioning in DSM IV TR 1. Such an analysis allows the qualitative comparison of functional 
level between HR samples and other psychiatric samples assessed with the GAF. Point estimates and dispersion 
measures have been computed applying random effect models given the high heterogeneity (HR: Q=362.23, 
I2=95.58%, df=16, p<0.001; healthy comparisons: Q=1364.33, I2=99.33%, df=9, p<0.001; psychosis comparisons: 
Q=145.48, I2=93.81%, df=9, p<0.001). 
A second supplementary analysis investigated the possible confounding effect of the HR diagnostic tool on cross 
sectional data. No difference emerged between studies adopting functioning as diagnostic criteria (e.g. using the 
latest version of Comprehensive Assessment for At Risk Mental State 6) in both HR vs healthy (between subgroup 
heterogeneity: Q=0.127, p=0.722, mixed effect model applied) and HR vs psychosis (between subgroup 
heterogeneity: Q=0.307, p=0.580, mixed effect model applied).  
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Table DS1. Merging of continuous variables 7 
 Subgroup 
1 
Subgroup 
2 
Combined group 
Sample 
size N1 N2 N1+ N2 
Mean M1 M2 
𝑁1𝑀1 + 𝑁2𝑀2
𝑁1 + 𝑁2  
SD 
SD1 SD2 �(𝑁1 − 1)𝑆𝐷12 + (𝑁2 − 1)𝑆𝐷22 + 𝑁1𝑁2𝑁1 + 𝑁2 (𝑀12 + 𝑀22 − 2𝑀1𝑀2)
𝑁1 + 𝑁2− 12  
M, mean; N, sample size; SD, standard deviation. 
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Table DS2a. Studies included in the meta-analyses 
Cross-sectional data 
    
HR 
 
Comparison 
Study name Functioning/QoL assessment 
HR diagnostic 
tool 
Quality 
(NOS)  
Sample 
size 
Female 
(%) 
Age 
(years)  Group 
Sample 
size 
Female 
(%) 
Age 
(years) 
Addington et al. 2008 8 SFS, QLS-role SIPS 5  86 43 19.4  Healthy 55 40 21.7 
         First-episode psychosis 50 40 25.1 
         Chronic psychosis 53 28 35.5 
Bechdolf et al. 2005 9 MSQoL ERIraos 7  45 31.1 25.7  First-episode psychosis 40 40 27.8 
Carrion et al. 2011 10 GF-social SIPS 7  127 33.1 16.9  Healthy 80 55 16 
Chudleigh et al. 2011 11 SOFAS CAARMS 6  20 45 22.75  Healthy 20 50 22 
         First-episode psychosis 20 35 22.05 
Chung et al. 2008 12 GAF CAARMS 7  33 42.4 20.8  Healthy 36 44.4 21.97 
Eastvold et al. 2007 13 GAF SIPS 7  40 49 20.8  First-episode psychosis 15 45 21.5 
Francey et al. 2005 14 QLS SIPS 6  70 47.1 20.1  Healthy 32 25 23.34 
Fulford et al. 2013 15 GAF SIPS 6  98 40.8 17.7  First-episode psychosis 88 28.4 21.28 
Hui et al. 2013 5 GAF-disability, MANSA CAARMS 7  60 48.3 20.2  Healthy 45 46.7 21.4 
Kim et al. 2013 16 QLS SIPS 7  60 41.6 19.7  Healthy 47 48.9 20.3 
Koren et al. 2013 17 GF-social SIPS 6  14 - -  Healthy 43 - - 
Lindgren et al. 2010 18 GAF SIPS 8  62 36.6 16.6  Healthy 112 - - 
Niendam et al. 2009 19 GAF SIPS 6  64 39.1 16.4  Healthy 26 58 17.67 
Niendam et al. 2013 20 GAF SOPS 7  25 44 16.9  First-episode psychosis 35 26 18.27 
Pruessner et al. 2011 21 GAF CAARMS 6  30 46.7 20.3  First-episode psychosis 32 43.8 22.72 
Quednow et al. 2008 22 GAF ERIraos 6  54 35 26.7  First-episode psychosis 31 45 34.7 
Rausch et al. 2013 23 GAF CAARMS 6  63 20.6 24.6  First-episode psychosis 22 27.27 28.5 
Ruhrmann et al. 2008 24 MSQoL ERIraos 7  215 37.7 25.8  Healthy 87 54 24.6 
Schlosser et al. 2012 25 GF-social SOPS 6  84 38.8 16.9  Healthy 58 52 17.9 
Serrani 2011 26 GAF CAARMS 7  27 19 17.4  Healthy 38 19 18.2 
Shin et al. 2013 27 GAF CAARMS 6  27 40.7 20.9  Healthy 38 39.47 22.4 
         First-episode psychosis 37 59.4 22.6 
Simon et al. 2012 28 GAF SOPS 6  99 38.4 20.7  Healthy 49 20 21.6 
         First-episode psychosis 48 33.3 22.4 
Smieskova et al. 2012 29 GAF BSIP 6  31 29 24.9  Healthy 19 47 26.58 
         First-episode psychosis 16 25 25.13 
Song et al. 2013 30 GF-social SIPS 6  50 40 20  First-episode psychosis 33 57.57 21.4 
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Cross-sectional data 
    
HR 
 
Comparison 
Study name Functioning/QoL assessment 
HR diagnostic 
tool 
Quality 
(NOS)  
Sample 
size 
Female 
(%) 
Age 
(years)  Group 
Sample 
size 
Female 
(%) 
Age 
(years) 
Stanford et al. 2011 31 GAF SIPS 5  63 20.6 19.6  Healthy 24 37.5 21 
Thompson et al. 2012 32 SOFAS CAARMS 8  30 53.3 19.1  Healthy 30 58.1 19.3 
         First-episode psychosis 40 37.5 20.5 
van Rijn et al. 2011 33 GAF SIPS 8  36 30.5 15.2  Healthy 23 43.47 15.9 
van Tricht et al. 2010 34 GAF SIPS 6  61 31.1 19.6  Healthy 26 53.5 20 
Washida et al. 2013 35 GAF CAARMS 6  17 70.6 23.7  First-episode psychosis 23 39.13 23.3 
         Chronic psychosis 21 47.62 26.3 
Woods et al. 2009 36 GAF SIPS 7  368 - -  Healthy 57 - - 
Legend: BSIP, Basel Screening Instrument for Psychosis; CAARMS, Comprehensive Assessment of At Risk Mental States; ERIraos, Early Recognition Inventory and Interview for the 
Retrospective Assessment of the Onset of Schizophrenia; GAF, Global Assessment of Functioning; GF-social, Global Functioning: social scale; HR, High Risk; MANSA, Manchester 
Short Assessment of Quality of Life; MSQoL, Modular System for Quality of Life; NOS, Newcastel-Ottawa Scale; QLS, Quality of Life Scale; QoL, Quality of Life; SFS, Social 
Functioning Scale; SIPS, Structured Interview for Prodromal Syndromes; SOFAS, Social and Occupational Functioning Assessment Scale; SOPS, Scale of Prodromal Symptoms
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Table DS2b. Studies included in the meta-analyses 
Longitudinal data 
   
 HR 
Study name Functioning/QoL assessment 
HR diagnostic 
tool 
Follow-up length 
(months) 
 
Sample size Female (%) Age (years) 
Bearden et al. 2011 37 GAF SIPS 14.8  54 29.63 17.4 
Bechdolf et al. 2010 38 SOFAS CAARMS 20.21  92 65.2 18 
Becker et al. 2010 39 GAF SIPS 18  41 30 19.7 
Brewer et al. 2005 40 GAF CAARMS 36  98 47.3 19.8 
Kim et al. 2011 41 GAF CAARMS 62.4  49 38.7 21.1 
Koutsouleris et al. 2012 42 GAF CAARMS 48  35 33.3 24.7 
Lam et al. 2006 43 GAF CAARMS 6  62 41.9 16.2 
Lemos-Giraldez et al. 2009 44 GAF SIPS 36  61 34.4 21.7 
Thompson et al. 2011 45 GAF CAARMS 28  104 51 19.4 
Ziermans et al. 2011 46 GAF SIPS 24  58 33.3 15.4 
Legend: BSIP, Basel Screening Instrument for Psychosis; CAARMS, Comprehensive Assessment of At Risk Mental States; ERIraos, Early Recognition Inventory and Interview for the 
Retrospective Assessment of the Onset of Schizophrenia; GAF, Global Assessment of Functioning; GF-social, Global Functioning: social scale; HR, High Risk; MANSA, Manchester 
Short Assessment of Quality of Life; MSQoL, Modular System for Quality of Life; NOS, Newcastel-Ottawa Scale; QLS, Quality of Life Scale; QoL, Quality of Life; SFS, Social 
Functioning Scale; SIPS, Structured Interview for Prodromal Syndromes; SOFAS, Social and Occupational Functioning Assessment Scale; SOPS, Scale of Prodromal Symptoms
 Table DS3. Quality criteria for the studies included in the meta-analyses 
Study name Selection Comparability Exposure NOS stars 
Addington et al. 2008 8    5 
Bechdolf et al. 2005 9    7 
Carrion et al. 2011 10    7 
Chudleigh et al. 2011 11    6 
Chung et al. 2008 12    7 
Eastvold et al. 2007 13    7 
Francey et al. 2005 14    6 
Fulford et al. 2013 15    6 
Hui et al. 2013 5    7 
Kim et al. 2013 16    7 
Koren et al. 2013 17    6 
Lindgren et al. 2010 18    8 
Niendam et al. 2009 19    6 
Niendam et al. 2013 20    7 
Pruessner et al. 2011 21    6 
Quednow et al. 2008 22    6 
Rausch et al. 2013 23    6 
Ruhrmann et al. 2008 24    7 
Schlosser et al. 2012 25    6 
Serrani 2011 26    7 
Shin et al. 2013 27    6 
Simon et al. 2012 28    6 
Smieskova et al. 2012 29    6 
Song et al. 2013 30    6 
Stanford et al. 2011 31    5 
Thompson et al. 2012 32    8 
van Rijn et al. 2011 33    8 
van Tricht et al. 2010 34    6 
Washida et al. 2013 35    6 
Woods et al. 2009 36    7 
Legend: NOS, Newcastle-Ottawa Scale 
Subsections: Selection (case definition, representativeness of the cases, selection of controls, definition of controls - max 4 stars); 
Comparability (on the basis of design: study controls for age, study controls for any additional factor - max 2 stars); Exposure 
(ascertainment of functioning or quality of life, same method of ascertainment for cases and controls, Non-Response rate - max 3 
stars). 
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Table DS4. Studies excluded from the meta-analyses 
Study name Year Exclusion criteria 
McGorry, et al. 47 1996 L-b 
Klosterkotter, et al. 48 2001 L-e 
McGorry, et al. 49 2002 CS-c, L-e 
Miller, et al. 50 2003 L-e 
Ruhrmann, et al. 51 2003 CS-a, L-a 
Yung, et al. 52 2003 CS-c, L-e 
Addington, et al. 53 2004 CS-a, L-a 
Francey, et al. 54 2004 CS-a, L-a 
Hawkins, et al. 55 2004 CS-d, L-c 
Mason, et al. 56 2004 CS-c, L-e 
Morrison, et al. 57 2004 L-d 
Phillips, et al. 58 2004 CS-a, L-a 
Yung, et al. 59 2004 CS-c, L-f 
Barnett, et al. 60 2005 CS-c, L-c 
Bechdolf, et al. 9 2005 L-c 
Brewer, et al. 40 2005 CS-d 
Cannon 61 2005 CS-a, L-a 
Francey, et al. 14 2005 L-f 
Hunt, et al. 62 2005 CS-a, L-a 
Amminger, et al. 63 2006 CS-c, L-e 
Becker, et al. 64 2006 CS-a, L-a 
Becker, et al. 65 2006 CS-a 
Becker, et al. 66 2006 CS-a 
Brewer, et al. 67 2006 CS-a, L-a 
Klaassen, et al. 68 2006 CS-a, L-a 
Lam, et al. 43 2006 CS-c 
Lencz, et al. 69 2006 CS-d, L-e 
Macedo, et al. 70 2006 CS-a, L-a 
McGlashan, et al. 71 2006 L-d 
Niendam, et al. 72 2006 CS-c, L-c 
Nordentoft, et al. 73 2006 L-d 
Silverstein, et al. 74 2006 CS-d, L-c 
Simon, et al. 75 2006 CS-d, L-c 
Trotman, et al. 76 2006 CS-b, L-b 
Wood, et al. 77 2006 CS-b, L-b 
Yung, et al. 78 2006 CS-d, L-e 
Yung, et al. 79 2006 CS-b, L-b 
Addington, et al. 80 2007 CS-a, L-a 
Ballon, et al. 81 2007 CS-e, L-c 
Berger, et al. 82 2007 CS-a, L-a 
Cannon, et al. 83 2007 CS-a, L-a 
Cornblatt, et al. 84 2007 L-e 
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Study name Year Exclusion criteria 
Cornblatt, et al. 2 2007 CS-c, L-e 
Czernikiewicz, et al. 85 2007 CS-a, L-a 
Eastvold, et al. 13 2007 L-e 
Jabben, et al. 86 2007 CS-b, L-b 
Killackey, et al. 87 2007 CS-a, L-a 
Kok, et al. 88 2007 CS-b, L-b 
Morrison, et al. 89 2007 L-e 
Myles-Worsley, et al. 90 2007 CS-d, L-c 
Nieman, et al. 91 2007 CS-d, L-c 
Niendam, et al. 92 2007 CS-c, L-c 
Niendam, et al. 93 2007 CS-c, L-f 
Niendam, et al. 94 2007 CS-a, L-a 
Patel, et al. 95 2007 CS-a, L-a 
Phillips, et al. 96 2007 CS-c, L-d 
Pinkham, et al. 97 2007 CS-d, L-c 
Sanderson, et al. 98 2007 CS-a, L-a 
Schultze-Lutter, et al. 99 2007 L-e 
Simon, et al. 100 2007 CS-d, L-c 
Svirskis, et al. 101 2007 CS-b 
Thompson, et al. 102 2007 CS-c, L-f 
Thompson, et al. 103 2007 CS-c, L-e 
Yung, et al. 104 2007 CS-c, L-e 
Addington, et al. 8 2008 L-c 
Cannon, et al. 105 2008 CS-c, L-e 
Chung, et al. 12 2008 L-c 
Corcoran, et al. 106 2008 CS-c, L-e 
De Masi, et al. 107 2008 CS-a, L-a 
Hurlemann, et al. 108 2008 CS-d, L-c 
Karlsgodt, et al. 109 2008 CS-a, L-a 
O'Brien, et al. 110 2008 CS-c, L-e 
Oezguerdal, et al. 111 2008 CS-d, L-c 
Quednow, et al. 22 2008 L-c 
Ruhrmann, et al. 24 2008 L-c 
Shim, et al. 112 2008 CS-c, L-f 
Shim, et al. 113 2008 CS-e, L-c 
Tarbox, et al. 114 2008 CS-a, L-a 
Willhite, et al. 115 2008 CS-c, L-e 
Yung, et al. 116 2008 L-e 
Fusar-Poli, et al. 117 2009 CS-c, L-e 
Grano, et al. 118 2009 CS-c, L-e 
Hauser, et al. 119 2009 CS-c, L-c 
Karlsgodt, et al. 120 2009 CS-d, L-e 
Keri, et al. 121 2009 CS-a, L-a 
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Study name Year Exclusion criteria 
Koutsouleris, et al. 122 2009 L-e 
Lemos-Giraldez, et al. 44 2009 CS-c 
Niendam, et al. 123 2009 CS-a, L-a 
Niendam, et al. 19 2009 L-c 
O'Brien, et al. 124 2009 CS-c, L-c 
Oezguerdal, et al. 125 2009 CS-d, L-c 
Phillips, et al. 126 2009 CS-c, L-e 
Riecher-Roessler, et al. 127 2009 L-e 
Simon, et al. 128 2009 CS-c, L-e 
Velthorst, et al. 129 2009 CS-c, L-f 
Woods, et al. 36 2009 L-e 
Yung, et al. 130 2009 CS-b, L-b 
Amminger, et al. 131 2010 CS-c, L-d 
Armando, et al. 132 2010 CS-b, L-b 
Becker, et al. 39 2010 CS-e 
Chung, et al. 133 2010 CS-c, L-c 
Compton, et al. 134 2010 CS-b, L-b 
Fusar-Poli, et al. 135 2010 CS-d, L-f 
Fusar-Poli, et al. 136 2010 CS-d, L-e 
Ilonen, et al. 137 2010 CS-d, L-c 
Jang, et al. 138 2010 CS-a, L-a 
Korver, et al. 139 2010 CS-d, L-c 
Koutsouleris, et al. 140 2010 CS-d, L-f 
Lindgren, et al. 18 2010 L-c 
Linszen, et al. 141 2010 CS-a, L-a 
Luebbe, et al. 142 2010 CS-b, L-b 
Machielsen, et al. 143 2010 CS-d, L-c 
Mittal, et al. 144 2010 L-e 
Nelson, et al. 145 2010 L-e 
Romano, et al. 146 2010 CS-b, L-b 
Ruhrmann, et al. 147 2010 CS-a, L-a 
Ruhrmann, et al. 148 2010 CS-c, L-e 
Sabb, et al. 149 2010 CS-e, L-f 
Schlosser, et al. 150 2010 CS-c, L-e 
Seidman, et al. 151 2010 CS-d, L-e 
Shim, et al. 152 2010 CS-e, L-c 
Simon, et al. 153 2010 L-f 
van Tricht, et al. 34 2010 L-f 
Velthorst, et al. 154 2010 CS-c, L-f 
Woodberry, et al. 155 2010 CS-d, L-c 
Addington, et al. 156 2011 CS-d, L-e 
Addington, et al. 157 2011 CS-c, L-e 
Bearden, et al. 37 2011 CS-e 
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Study name Year Exclusion criteria 
Bechdolf, et al. 158 2011 CS-a, L-a 
Bruene, et al. 159 2011 CS-d, L-e 
Carrion, et al. 10 2011 L-c 
Chudleigh, et al. 11 2011 L-c 
Collip, et al. 160 2011 CS-b, L-b 
Corcoran, et al. 161 2011 CS-e, L-c 
Fontenelle, et al. 162 2011 CS-c, L-e 
Frommann, et al. 163 2011 CS-d, L-c 
Fusar-Poli, et al. 164 2011 CS-d, L-f 
Fusar-Poli, et al. 165 2011 CS-d, L-f 
Gee, et al. 166 2011 CS-a, L-a 
Grano, et al. 167 2011 CS-c, L-e 
Grano, et al. 168 2011 CS-d, L-c 
Jang, et al. 169 2011 CS-d, L-f 
Keshavan, et al. 170 2011 CS-a, L-a 
Kim, et al. 41 2011 CS-d 
Lin, et al. 171 2011 CS-c, L-e 
Mees, et al. 172 2011 L-a 
Mittal, et al. 173 2011 CS-c, L-e 
Mukkala, et al. 174 2011 CS-d, L-c 
Niendam, et al. 175 2011 CS-a, L-a 
Pruessner, et al. 21 2011 L-c 
Raballo, et al. 176 2011 CS-c, L-e 
Rauchensteiner, et al. 177 2011 CS-d, L-c 
Rietdijk, et al. 178 2011 CS-c, L-c 
Serrani 26 2011 L-c 
Simeonova, et al. 179 2011 CS-c, L-e 
Song, et al. 180 2011 CS-b, L-b 
Stanford, et al. 31 2011 L-c 
Thompson, et al. 45 2011 CS-c 
van Rijn, et al. 181 2011 CS-e, L-c 
van Rijn, et al. 33 2011 L-c 
Velthorst, et al. 182 2011 CS-c, L-f 
Yung, et al. 183 2011 CS-c, L-e 
Addington, et al. 184 2012 CS-a, L-a 
Amminger, et al. 185 2012 CS-d, L-c 
Armando, et al. 186 2012 CS-c, L-c 
Armando, et al. 187 2012 CS-c, L-c 
Bechdolf, et al. 188 2012 CS-c, L-d 
Bowie, et al. 189 2012 CS-d, L-e 
Cornblatt, et al. 190 2012 CS-c, L-d 
Demjaha, et al. 191 2012 L-f 
Fusar-Poli, et al. 192 2012 CS-a, L-a 
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Study name Year Exclusion criteria 
Fusar-Poli, et al. 193 2012 CS-a, L-a 
Hur, et al. 194 2012 CS-e, L-c 
Jaracz, et al. 195 2012 CS-a, L-a 
Kelleher, et al. 196 2012 CS-d, L-c 
Koutsouleris, et al. 42 2012 CS-d 
Lavoie, et al. 197 2012 CS-c, L-e 
Lee, et al. 198 2012 CS-b, L-b 
Lin, et al. 199 2012 L-a 
Marques, et al. 200 2012 CS-d, L-c 
Marshall, et al. 201 2012 CS-c, L-e 
Masillo, et al. 202 2012 CS-d, L-c 
Morrison, et al. 203 2012 CS-c, L-e 
Quijada, et al. 204 2012 CS-c, L-e 
Rao, et al. 205 2012 CS-a, L-a 
Remberk, et al. 206 2012 CS-b, L-b 
Rietdijk, et al. 207 2012 CS-c, L-e 
Schlosser, et al. 25 2012 L-f 
Schultze-Lutter, et al. 208 2012 CS-d, L-e 
Simon, et al. 28 2012 L-e 
Smieskova, et al. 29 2012 L-e 
Song, et al. 209 2012 CS-a, L-a 
Stain, et al. 210 2012 CS-a, L-a 
Strobl, et al. 211 2012 CS-a, L-a 
Thompson, et al. 32 2012 L-c 
Tomassini, et al. 212 2012 CS-a, L-a 
Valli, et al. 213 2012 CS-a, L-a 
214
 2012 L-d 
Verma, et al. 215 2012 CS-c, L-e 
Addington, et al. 216 2013 CS-d, L-c 
Amminger, et al. 217 2013 CS-c, L-e 
Bugra, et al. 218 2013 CS-d, L-c 
Comparelli, et al. 219 2013 CS-c, L-c 
De Herdt, et al. 220 2013 CS-a, L-a 
Debbane, et al. 221 2013 CS-b, L-b 
Fulford, et al. 15 2013 L-c 
Fusar-Poli, et al. 222 2013 CS-a, L-a 
Gerlinger, et al. 223 2013 CS-a, L-a 
Grano, et al. 224 2013 CS-c, L-c 
Hui, et al. 5 2013 L-e 
Hur, et al. 225 2013 CS-d, L-c 
Jalbrzikowski, et al. 226 2013 CS-e, L-e 
Kelleher, et al. 227 2013 CS-d, L-c 
Kim, et al. 16 2013 L-e 
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Study name Year Exclusion criteria 
Kline, et al. 228 2013 CS-d, L-c 
Koren, et al. 17 2013 L-c 
Lecardeur 229 2013 CS-a, L-a 
Lee, et al. 230 2013 L-e 
Lin, et al. 231 2013 CS-a, L-a 
Lin, et al. 232 2013 CS-c, L-e 
McGorry, et al. 233 2013 CS-c, L-e 
Mossaheb, et al. 234 2013 CS-c, L-e 
Mueller, et al. 235 2013 CS-a, L-a 
Nelson, et al. 236 2013 CS-c, L-e 
Nieman, et al. 237 2013 CS-c, L-e 
Niendam, et al. 238 2013 CS-a, L-a 
Rapp, et al. 239 2013 CS-d, L-c 
Ratheesh, et al. 240 2013 CS-d, L-f 
Rausch, et al. 23 2013 L-c 
Riecher-Roessler, et al. 241 2013 CS-a, L-a 
Shin, et al. 27 2013 L-c 
Song, et al. 30 2013 L-e 
Stafford, et al. 242 2013 CS-a, L-a 
Stowkowy, et al. 243 2013 CS-e 
Sullivan, et al. 244 2013 CS-b, L-b 
Taylor, et al. 245 2013 CS-c, L-c 
Teyssier 246 2013 CS-a, L-a 
Thompson, et al. 247 2013 CS-e, L-c 
Tiffin, et al. 248 2013 CS-a, L-a 
Tikka, et al. 249 2013 CS-d, L-c 
Valmaggia, et al. 250 2013 CS-c, L-e 
Velthorst, et al. 251 2013 CS-c, L-e 
Walder, et al. 252 2013 CS-c, L-e 
Washida, et al. 35 2013 L-e 
Zaytseva, et al. 253 2013 CS-a, L-a 
Niendam, et al. 20 2014 L-c 
Legend: HR, High Risk 
Exclusion criteria for meta-analysis 1 and 2: 
CS-a: Review, not original article written in English published on peer reviewed journal; CS-b: Missing HR 
diagnosis; CS-c: No comparison group; CS-d: No data for meta-analysis; CS-e: Overlapping dataset. 
Exclusion criteria for meta-analysis 3: 
L-a: Review, not original article written in English pubblished on peer reviewed journal; L-b: Missing HR 
diagnosis; L-c: No follow-up; L-d: No observational design; L-e: No data for meta-analysis; L-f: Overlapping 
dataset;
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Fig. DS1. PRISMA flow charts. Selection of articles comparing cross-sectional functioning (a, meta-analysis 1) and quality of 
life (b, meta-analysis 2) in HR subject vs. healthy comparisons and comparisons with psychosis; selection of longitudinal studies 
comparing baseline functioning in HR subjects who did and did not develop psychosis at follow-up (c, meta-analysis 3). 
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Fig. DS2. Meta-regressions of standardised difference in functioning between HR and psychosis 
(PS) and proportion of females, in the HR (a) or PS group (b). 
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Fig. DS3. Supplementary meta-analysis of mean GAF score in HR, healthy (HC) and psychotic 
subjects (PS). HR mean GAF=50.38 (95% CI from 47.03 to 53.73, sample size=830); HC mean 
GAF=79.46 (95% CI from 73.40 to 85.52, sample size=391); PS mean GAF=44.72 (95% CI 
from 40.21 to 49.23, sample size=368). 
 
Study nameSubgroup Statistics for each study
Lower Upper 
Mean limit limit p-Value
Van Rijn et al. 2011HC 91.300 88.398 94.202 <0.001
Shin et al. 2013HC 88.600 87.996 89.204 <0.001
Smieskova et al.2012HC 88.600 86.577 90.623 <0.001
Van Tricht et al. 2010HC 87.600 85.102 90.098 <0.001
Serrani et al. 2011HC 87.400 85.947 88.853 <0.001
Chung et al. 2008HC 83.860 82.981 84.739 <0.001
Niendam et al. 2009HC 81.540 77.577 85.503 <0.001
Stanford et al. 2011HC 80.600 77.119 84.081 <0.001
Lindgren et al. 2010HC 52.400 50.029 54.771 <0.001
Simon et al. 2012HC 52.300 49.192 55.408 <0.001
79.462 73.404 85.521 <0.001
Smieskova et al.2012HR 66.600 61.235 71.965 <0.001
Pruessner et al. 2011HR 61.270 56.754 65.786 <0.001
Van Rijn et al. 2011HR 59.300 54.890 63.710 <0.001
Chung et al. 2008HR 59.180 56.188 62.172 <0.001
Quednow et al. 2008HR 58.000 55.061 60.939 <0.001
Niendam et al. 2013HR 54.880 51.058 58.702 <0.001
Eastvold et al. 2007HR 53.500 50.339 56.661 <0.001
Raush et al. 2013HR 51.900 49.085 54.715 <0.001
Van Tricht et al. 2010HR 50.060 47.052 53.068 <0.001
Shin et al. 2013HR 49.500 46.973 52.027 <0.001
Fulford et al. 2013HR 47.950 45.814 50.086 <0.001
Niendam et al. 2009HR 45.140 41.982 48.298 <0.001
Serrani et al. 2011HR 44.230 41.065 47.395 <0.001
Simon et al. 2012HR 43.720 41.971 45.469 <0.001
Stanford et al. 2011HR 43.600 41.797 45.403 <0.001
Lindgren et al. 2010HR 38.100 35.113 41.087 <0.001
Washida et al. 2013HR 29.700 23.283 36.117 <0.001
50.379 47.025 53.733 <0.001
Pruessner et al. 2011PS 52.590 46.191 58.989 <0.001
Quednow et al. 2008PS 52.060 45.266 58.854 <0.001
Shin et al. 2013PS 49.900 46.581 53.219 <0.001
Smieskova et al.2012PS 49.600 40.878 58.322 <0.001
Eastvold et al. 2007PS 47.600 43.855 51.345 <0.001
Niendam et al. 2013PS 46.030 42.359 49.701 <0.001
Fulford et al. 2013PS 44.350 42.148 46.552 <0.001
Raush et al. 2013PS 42.950 38.838 47.062 <0.001
Simon et al. 2012PS 35.500 33.803 37.197 <0.001
Washida et al. 2013PS 29.741 25.211 34.271 <0.001
44.715 40.216 49.213 <0.001
Mean and 95% CI
0.00 50.00 100.00
Overall HC Random
Overall HR Random
Overall PS Random
Relative weight
9.95
10.17
10.06
10.01
10.12
10.16
9.75
9.85
10.02
9.91
5.81
5.41
5.99
5.98
6.17
6.18
5.99
5.67
6.02
5.95
5.95
6.07
5.98
6.13
5.64
5.95
5.11
10.44
10.96
9.17
10.29
10.61
7.91
11.08
10.47
8.96
10.10
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Fig. DS4. Supplementary meta-analysis comparing the Comprehensive Assessment of At Risk 
Mental State (CAARMS) and other HR assessment tools. In each analysis (HR vs healthy or 
psychotic comparison) no significant between subgroup heterogeneity emerged (HR vs healthy: 
Q=0.127, p=0.722; HR vs psychosis: Q=0.307, p=0.580) thus, the findings are not modulated by 
the HR diagnostic tool. 
 
CAARMS Chudleigh et al. 2011 SOFAS -0.543 -1.162 0.076 0.086
CAARMS Shin et al. 2013 GAF -0.044 -0.534 0.446 0.860
CAARMS Smieskova et al.2012 GAF 1.036 0.407 1.665 0.001
CAARMS Thompson et al. 2012 SOFAS 0.375 -0.098 0.847 0.120
Overall CAARMS Random 0.203 -0.383 0.789 0.498
Other Addington et al. 2008 SFS -0.318 -0.605 -0.031 0.030
Other Eastvold et al. 2007 GAF 0.610 0.014 1.206 0.045
Other Fulford et al. 2013 GAF 0.336 0.047 0.625 0.023
Other Niendam et al. 2013 GAF 0.828 0.300 1.356 0.002
Other Pruessner et al. 2011 GAF 0.539 0.038 1.039 0.035
Other Quednow et al. 2008 GAF 0.404 -0.038 0.846 0.073
Other Raush et al. 2013 GAF 0.804 0.308 1.300 0.001
Other Simon et al. 2012 GAF 1.015 0.653 1.377 <0.001
Other Song et al. 2013 GF-social -0.198 -0.635 0.238 0.374
Other Washida et al. 2013 GAF -0.003 -0.555 0.550 0.992
Overall Other Random 0.390 0.079 0.702 0.014
-2.00 -1.00 0.00 1.00 2.00
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Total between: Q = 0.127, df = 1, p = 0.722
Study name Outcome Statistics for each study Hedges's g and 95% CI
Hedges's Lower Upper 
g limit limit p-Value
HR vs. healthy comparisons
Subgroup
CAARMS Chudleigh et al. 2011 SOFAS -5.680 -7.065 -4.295 <0.001
CAARMS Hui et al. 2013 GAF-disability-5.047 -5.830 -4.264 <0.001
CAARMS Koren et al. 2013 GF-social -0.986 -1.608 -0.365 0.002
CAARMS Schlosser et al. 2012 GF-social -1.948 -2.351 -1.546 <0.001
CAARMS Simon et al. 2012 GAF -0.883 -1.238 -0.528 <0.001
Overall CAARMS Random -2.809 -4.238 -1.379 <0.001
Other Addington et al. 2008 SFS -1.657 -2.046 -1.269 <0.001
Other Carrion et al. 2011 GF-social -1.997 -2.336 -1.658 <0.001
Other Chung et al. 2008 GAF -3.834 -4.626 -3.042 <0.001
Other Lindgren et al. 2010 GAF -1.137 -1.468 -0.806 <0.001
Other Niendam et al. 2009 GAF -2.955 -3.580 -2.330 <0.001
Other Serrani et al. 2011 GAF -6.636 -7.876 -5.395 <0.001
Other Shin et al. 2013 GAF -8.502 -10.043 -6.962 <0.001
Other Smieskova et al.2012 GAF -1.752 -2.411 -1.093 <0.001
Other Stanford et al. 2011 GAF -4.760 -5.607 -3.913 <0.001
Other Thompson et al. 2012 SOFAS -2.357 -3.010 -1.703 <0.001
Other Van Rijn et al. 2011 GAF -2.755 -3.472 -2.038 <0.001
Other Van Tricht et al. 2010 GAF -3.487 -4.177 -2.798 <0.001
Other Woods et al. 2009 GAF -0.356 -0.636 -0.077 0.012
Overall Other Random -3.107 -3.915 -2.299 <0.001
23.67
26.26
23.47
26.61
11.43
8.65
11.42
9.28
9.54
10.09
9.58
10.81
10.14
9.05
Relative weight
Relative weight
17.72
19.98
20.43
20.90
20.98
8.09
8.13
7.64
8.13
7.86
6.91
6.35
7.82
7.56
7.82
7.74
7.78
8.17
 18 
 
References 
 
1. Association AP. Diagnostic and statistical manual of mental disorders: DSM-IV-TR®. American 
Psychiatric Publishing, 2000. 
2. Cornblatt BA, Auther AM, Niendam T, Smith CW, Zinberg J, Bearden CE, et al. Preliminary 
Findings for Two New Measures of Social and Role Functioning in the Prodromal Phase of Schizophrenia. 
Schizophr Bull. 2007; 33(3): 688-702. 
3. Heinrichs DW, Hanlon TE, Carpenter WT, Jr. The Quality of Life Scale: an instrument for rating 
the schizophrenic deficit syndrome. Schizophr Bull. 1984; 10(3): 388-98. 
4. Pukrop R, Moller HJ, Steinmeyer EM. Quality of life in psychiatry: a systematic contribution to 
construct validation and the development of the integrative assessment tool "modular system for 
quality of life". Eur Arch Psychiatry Clin Neurosci. 2000; 250(3): 120-32. 
5. Hui C, Morcillo C, Russo DA, Stochl J, Shelley GF, Painter M, et al. Psychiatric morbidity, 
functioning and quality of life in young people at clinical high risk for psychosis. Schizophr Res. 2013; 
148(1-3): 175-80. 
6. Yung A, Philips L, Simmons M, Ward J, Thompson K, French P. CAARMS: Comprehensive 
Assessment of At Risk Mental States. The PACE Clinic, 2006. 
7. Higgins JP, Green S, Collaboration C. Cochrane handbook for systematic reviews of interventions. 
Wiley Online Library, 2008. 
8. Addington J, Penn D, Woods SW, Addington D, Perkins DO. Social functioning in individuals at 
clinical high risk for psychosis. Schizophr Res. 2008; 99(1-3): 119-24. 
9. Bechdolf A, Pukrop R, Kohn D, Tschinkel S, Veith V, Schultze-Lutter F, et al. Subjective quality of 
life in subjects at risk for a first episode of psychosis: A comparison with first episode schizophrenia 
patients and healthy controls. Schizophr Res. 2005; 79(1): 137-43. 
10. Carrion RE, Goldberg TE, McLaughlin D, Auther AM, Correll CU, Cornblatt BA. Impact of 
neurocognition on social and role functioning in individuals at clinical high risk for psychosis. Am J 
Psychiatry. 2011; 168(8): 806-13. 
11. Chudleigh C, Naismith SL, Blaszczynski A, Hermens DF, Hodge MA, Hickie IB. How does social 
functioning in the early stages of psychosis relate to depression and social anxiety? Early Interv 
Psychiatry. 2011; 5(3): 224-32. 
12. Chung YS, Kang D-H, Shin NY, Yoo SY, Kwon JS. Deficit of theory of mind in individuals at ultra-
high-risk for schizophrenia. Schizophr Res. 2008; 99(1-3): 111-8. 
13. Eastvold AD, Heaton RK, Cadenhead KS. Neurocognitive deficits in the (putative) prodrome and 
first episode of psychosis. Schizophr Res. 2007; 93(1-3): 266-77. 
14. Francey SM, Jackson HJ, Phillips LJ, Wood SJ, Yung AR, McGorry PD. Sustained attention in young 
people at high risk of psychosis does not predict transition to psychosis. Schizophr Res. 2005; 79(1): 127-
36. 
 19 
 
15. Fulford D, Niendam TA, Floyd EG, Carter CS, Mathalon DH, Vinogradov S, et al. Symptom 
dimensions and functional impairment in early psychosis: More to the story than just negative 
symptoms. Schizophr Res. 2013; 147(1): 125-31. 
16. Kim KR, Song YY, Park JY, Lee EH, Lee M, Lee SY, et al. The relationship between psychosocial 
functioning and resilience and negative symptoms in individuals at ultra-high risk for psychosis. Aust N Z 
J Psychiatry. 2013; 47(8): 762-71. 
17. Koren D, Reznik N, Adres M, Scheyer R, Apter A, Steinberg T, et al. Disturbances of basic self and 
prodromal symptoms among non-psychotic help-seeking adolescents. Psychol Med. 2013; 43(7): 1365-
76. 
18. Lindgren M, Manninen M, Laajasalo T, Mustonen U, Kalska H, Suvisaari J, et al. The relationship 
between psychotic-like symptoms and neurocognitive performance in a general adolescent psychiatric 
sample. Schizophr Res. 2010; 123(1): 77-85. 
19. Niendam TA, Berzak J, Cannon TD, Bearden CE. Obsessive compulsive symptoms in the psychosis 
prodrome: Correlates of clinical and functional outcome. Schizophr Res. 2009; 108(1-3): 170-5. 
20. Niendam TA, Lesh TA, Yoon J, Westphal AJ, Hutchison N, Daniel Ragland J, et al. Impaired 
context processing as a potential marker of psychosis risk state. Psychiatry Res. 2014; 221(1): 13-20. 
21. Pruessner M, Iyer SN, Faridi K, Joober R, Malla AK. Stress and protective factors in individuals at 
ultra-high risk for psychosis, first episode psychosis and healthy controls. Schizophr Res. 2011; 129(1): 
29-35. 
22. Quednow BB, Frommann I, Berning J, Kuehn K-U, Maier W, Wagner M. Impaired Sensorimotor 
Gating of the Acoustic Startle Response in the Prodrome of Schizophrenia. Biol Psychiatry. 2008; 64(9): 
766-73. 
23. Rausch F, Eifler S, Esser A, Esslinger C, Schirmbeck F, Meyer-Lindenberg A, et al. The Early 
Recognition Inventory ERIraos detects at risk mental states of psychosis with high sensitivity. Compr 
Psychiatry. 2013; 54(7): 1068-76. 
24. Ruhrmann S, Paruch J, Bechdolf A, Pukrop R, Wagner M, Berning J, et al. Reduced subjective 
quality of life in persons at risk for psychosis. Acta Psychiatr Scand. 2008; 117(5): 357-68. 
25. Schlosser DA, Jacobson S, Chen Q, Sugar CA, Niendam TA, Li G, et al. Recovery From an At-Risk 
State: Clinical and Functional Outcomes of Putatively Prodromal Youth Who Do Not Develop Psychosis. 
Schizophr Bull. 2012; 38(6): 1225-33. 
26. Serrani D. Neurocognitive assessment of ultra high risk of psychosis states using the MATRICS 
battery (Measurement and Treatment Research to Improve Cognition in Schizophrenia). Rev Psiquiatr 
Clín. 2011; 38(4): 130-4. 
27. Shin YS, Kim SN, Shin NY, Jung WH, Hur JW, Byun MS, et al. Increased intra-individual variability 
of cognitive processing in subjects at risk mental state and schizophrenia patients. In: PLoS One: 
e783542013. 
28. Simon AE, Graedel M, Cattapan-Ludewig K, Gruber K, Ballinari P, Roth B, et al. Cognitive 
functioning in at-risk mental states for psychosis and 2-year clinical outcome. Schizophr Res. 2012; 
142(1-3): 108-15. 
29. Smieskova R, Fusar-Poli P, Aston J, Simon A, Bendfeldt K, Lenz C, et al. Insular volume 
abnormalities associated with different transition probabilities to psychosis. Psychol Med. 2012; 42(8): 
1613-25. 
 20 
 
30. Song YY, Kang JI, Kim SJ, Lee MK, Lee E, An SK. Temperament and character in individuals at 
ultra-high risk for psychosis and with first-episode schizophrenia: Associations with psychopathology, 
psychosocial functioning, and aspects of psychological health. Compr Psychiatry. 2013; 54(8): 1161-8. 
31. Stanford AD, Messinger J, Malaspina D, Corcoran CM. Theory of Mind in patients at clinical high 
risk for psychosis. Schizophr Res. 2011; 131(1-3): 11-7. 
32. Thompson A, Papas A, Bartholomeusz C, Allott K, Amminger GP, Nelson B, et al. Social cognition 
in clinical "at risk" for psychosis and first episode psychosis populations. Schizophr Res. 2012; 141(2-3): 
204-9. 
33. van Rijn S, Aleman A, de Sonneville L, Sprong M, Ziermans T, Schothorst P, et al. Misattribution 
of facial expressions of emotion in adolescents at increased risk of psychosis: the role of inhibitory 
control. Psychol Med. 2011; 41(3): 499-508. 
34. van Tricht MJ, Nieman DH, Koelman JHTM, van der Meer JN, Bour LJ, de Haan L, et al. Reduced 
Parietal P300 Amplitude is Associated with an Increased Risk for a First Psychotic Episode. Biol 
Psychiatry. 2010; 68(7): 642-8. 
35. Washida K, Takeda T, Habara T, Sato S, Oka T, Tanaka M, et al. Efficacy of second-generation 
antipsychotics in patients at ultra-high risk and those with first-episode or multi-episode schizophrenia. 
Neuropsychiatr Dis Treat. 2013; 9: 861-8. 
36. Woods SW, Addington J, Cadenhead KS, Cannon TD, Cornblatt BA, Heinssen R, et al. Validity of 
the Prodromal Risk Syndrome for First Psychosis: Findings From the North American Prodrome 
Longitudinal Study. Schizophr Bull. 2009; 35(5): 894-908. 
37. Bearden CE, Wu KN, Caplan R, Cannon TD. Thought Disorder and Communication Deviance as 
Predictors of Outcome in Youth at Clinical High Risk for Psychosis. J Am Acad Child Adolesc Psychiatry. 
2011; 50(7): 669-80. 
38. Bechdolf A, Thompson A, Nelson B, Cotton S, Simmons MB, Amminger GP, et al. Experience of 
trauma and conversion to psychosis in an ultra-high-risk (prodromal) group. Acta Psychiatr Scand. 2010; 
121(5): 377-84. 
39. Becker HE, Nieman DH, Wiltink S, Dingemans PM, de Fliert JRv, Velthorst E, et al. Neurocognitive 
functioning before and after the first psychotic episode: does psychosis result in cognitive deterioration? 
Psychol Med. 2010; 40(10): 1599-606. 
40. Brewer WJ, Francey SM, Wood SJ, Jackson HJ, Pantelis C, Phillips LJ, et al. Memory impairments 
identified in people at ultra-high risk for psychosis who later develop first-episode psychosis. Am J 
Psychiatry. 2005; 162(1): 71-8. 
41. Kim HS, Shin NY, Jang JH, Kim E, Shim G, Park HY, et al. Social cognition and neurocognition as 
predictors of conversion to psychosis in individuals at ultra-high risk. Schizophr Res. 2011; 130(1-3): 170-
5. 
42. Koutsouleris N, Davatzikos C, Bottlender R, Patschurek-Kliche K, Scheuerecker J, Decker P, et al. 
Early Recognition and Disease Prediction in the At-Risk Mental States for Psychosis Using Neurocognitive 
Pattern Classification. Schizophr Bull. 2012; 38(6): 1200-15. 
43. Lam MML, Hung SF, Chen EYH. Transition to psychosis: 6-month follow-up of a Chinese high-risk 
group in Hong Kong. Aust N Z J Psychiatry. 2006; 40(5): 414-20. 
 21 
 
44. Lemos-Giraldez S, Vallina-Fernandez O, Fernandez-Iglesias P, Vallejo-Seco G, Fonseca-Pedrero E, 
Paino-Pineiro M, et al. Symptomatic and functional outcome in youth at ultra-high risk for psychosis: A 
longitudinal study. Schizophr Res. 2009; 115(2-3): 121-9. 
45. Thompson A, Nelson B, Yung A. Predictive validity of clinical variables in the "at risk" for 
psychosis population: International comparison with results from the North American Prodrome 
Longitudinal Study. Schizophr Res. 2011; 126(1-3): 51-7. 
46. Ziermans TB, Schothorst PF, Sprong M, van Engeland H. Transition and remission in adolescents 
at ultra-high risk for psychosis. Schizophr Res. 2011; 126(1-3): 58-64. 
47. McGorry PD, Edwards J, Mihalopoulos C, Harrigan SM, Jackson HJ. EPPIC: An evolving system of 
early detection and optimal management. Schizophr Bull. 1996; 22(2): 305-26. 
48. Klosterkotter J, Hellmich M, Steinmeyer EM, Schultze-Lutter F. Diagnosing schizophrenia in the 
initial prodromal phase. Arch Gen Psychiatry. 2001; 58(2): 158-64. 
49. McGorry PD, Yung AR, Phillips LJ, Yuen HP, Francey S, Cosgrave EM, et al. Randomized controlled 
trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical 
sample with subthreshold symptoms. Arch Gen Psychiatry. 2002; 59(10): 921-8. 
50. Miller TJ, McGlashan TH, Rosen JL, Cadenhead K, Ventura J, McFarlane W, et al. Interview for 
prodromal syndromes and the scale of prodromal symptoms: Predictive validity, interrater reliability, 
and training to reliability. Schizophr Bull. 2003; 29(4): 703-15. 
51. Ruhrmann S, Schultze-Lutter F, Klosterkotter J. Early detection and intervention in the initial 
prodromal phase of schizophrenia. Pharmacopsychiatry. 2003; 36 Suppl 3: S162-7. 
52. Yung AR, Phillips LJ, Yuen HP, Francey SM, McFarlane CA, Hallgren M, et al. Psychosis prediction: 
12-month follow up of a high-risk ("prodromal") group. Schizophr Res. 2003; 60(1): 21-32. 
53. Addington J, Zipursky R, Perkins D, Woods SW, Miller TJ, McGlashan TH. Decline in social 
functioning for those with an "at risk mental state". Schizophr Res. 2004; 70(1): 37-. 
54. Francey S, Brewer W, Wood S, Phillips L, Proffitt I, Jackson H, et al. Neuropsychological 
functioning in young people at ultra-high-risk of developing psychosis: Findings from the PACE Clinic. 
Schizophr Res. 2004; 70(1): 26-. 
55. Hawkins KA, Addington J, Keefe RSE, Christensen B, Perkins DO, Zipurksy R, et al. 
Neuropsychological status of subjects at high risk for a first episode of psychosis. Schizophr Res. 2004; 
67(2-3): 115-22. 
56. Mason O, Startup M, Halpin S, Schall U, Conrad A, Carr V. Risk factors for transition to first 
episode psychosis among individuals with 'at-risk mental states'. Schizophr Res. 2004; 71(2-3): 227-37. 
57. Morrison AP, French P, Walford L, Lewis SW, Kilcommons A, Green J, et al. Cognitive therapy for 
the prevention of psychosis in people at ultra-high risk - Randomised controlled trial. Br J Psychiatry. 
2004; 185: 291-7. 
58. Phillips L, Thompson K, Komesaroff P, Yuen HP, Jones S, Kelly D, et al. HPA-axis functioning and 
the onset of psychosis in an 'ultra' high-risk group. Schizophr Res. 2004; 70(1): 15-6. 
59. Yung AR, Phillips LJ, Yuen HP, McGorry PD. Risk factors for psychosis in an ultra high-risk group: 
psychopathology and clinical features. Schizophr Res. 2004; 67(2-3): 131-42. 
 22 
 
60. Barnett JH, Sahakian BJ, Werners U, Hill KE, Brazil R, Gallagher O, et al. Visuospatial learning and 
executive function are independently impaired in first-episode psychosis. Psychol Med. 2005; 35(7): 
1031-41. 
61. Cannon TD. Clinical and genetic high-risk strategies in understanding vulnerability to psychosis. 
Schizophr Res. 2005; 79(1): 35-44. 
62. Hunt SA, Schall U, Halpin SA, Beckmann CJ, Carr V. Neurocognitive profiles of prodromal 
psychosis. Schizophr Bull. 2005; 31(2): 326-7. 
63. Amminger GP, Leicester S, Yung AR, Phillips LJ, Berger GE, Francey SM, et al. Early-onset of 
symptoms predicts conversion to non-affective psychosis in ultra-high risk individuals. Schizophr Res. 
2006; 84(1): 67-76. 
64. Becker HE, Nieman DH, van de Fliert JR, Dingemans PM, Linszen DH. Cognitive functioning in 
patients at ultra high risk for psychosis: Relation with daily life functioning. Schizophr Res. 2006; 86: S90-
S. 
65. Becker HE, Nieman DH, Van De Fliert JR, Dingemans PM, Linszen DH. Cognitive functioning in 
patients at ultra high risk for developing psychosis. Schizophr Res. 2006; 81: 259-. 
66. Becker HE, Nieman DH, Van De Fliert JR, Dingemans PM, Linszen DH. Cognitive functioning in 
patients at ultra high risk for a first episode of psychosis: Relation to daily life functioning. Schizophr Res. 
2006; 81: 259-. 
67. Brewer WJ, Wood SJ, Phillips LJ, Francey SM, Pantelis C, Yung AR, et al. Generalized and specific 
cognitive performance in clinical high-risk cohorts: A review highlighting potential vulnerability markers 
for psychosis. Schizophr Bull. 2006; 32(3): 538-55. 
68. Klaassen MC, Nieman DH, Becker HE, Linszen DH. Is there any point in detecting high risk factors 
prior to a first psychosis? Tijdschrift voor psychiatrie. 2006; 48(6): 467-76. 
69. Lencz T, Smith CW, McLaughlin D, Auther A, Nakayama E, Hovey L, et al. Generalized and specific 
neurocognitive deficits in prodromal schizophrenia. Biol Psychiatry. 2006; 59(9): 863-71. 
70. Macedo G, Azevedo Y, Furrier A, Monteiro LC, Xavier JCM, Castro LSL, et al. Demographic 
characteristics of subjects at risk for psychosis in Sao Paulo, Brazil: First results. Schizophr Res. 2006; 81: 
266-. 
71. McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW, et al. Randomized, 
double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J 
Psychiatry. 2006; 163(5): 790-9. 
72. Niendam TA, Bearden CE, Johnson JK, McKinley M, Loewy R, O'Brien M, et al. Neurocognitive 
performance and functional disability in the psychosis prodrome. Schizophr Res. 2006; 84(1): 100-11. 
73. Nordentoft M, Thorup A, Petersen L, Ohlenschlaeger J, Melau M, Christensen TO, et al. 
Transition rates from schizotypal disorder to psychotic disorder for first-contact patients included in the 
OPUS trial. A randomized clinical trial of integrated treatment and standard treatment. Schizophr Res. 
2006; 83(1): 29-40. 
74. Silverstein S, Uhlhaas PJ, Essex B, Halpin S, Schall U, Carr V. Perceptual organization in first 
episode schizophrenia and ultra-high-risk states. Schizophr Res. 2006; 83(1): 41-52. 
75. Simon AE, Dvorsky DN, Boesch J, Roth B, Isler E, Schueler P, et al. Defining subjects at risk for 
psychosis: A comparison of two approaches. Schizophr Res. 2006; 81(1): 83-90. 
 23 
 
76. Trotman H, McMillan A, Walker E. Cognitive function and symptoms in adolescents with 
schizotypal personality disorder. Schizophr Bull. 2006; 32(3): 489-97. 
77. Wood SJ, Berger GE, Lambert M, Conus P, Velakoulis D, Stuart GW, et al. Prediction of functional 
outcome 18 months after a first psychotic episode - A proton magnetic resonance spectroscopy study. 
Arch Gen Psychiatry. 2006; 63(9): 969-76. 
78. Yung AR, Stanford C, Cosgrave E, Killackey E, Phillips L, Nelson B, et al. Testing the Ultra High Risk 
(prodromal) criteria for the prediction of psychosis in a clinical sample of young people. Schizophr Res. 
2006; 84(1): 57-66. 
79. Yung AR, Buckby JA, Cotton SM, Cosgrave EM, Killackey EJ, Stanford C, et al. Psychotic-like 
experiences in nonpsychotic help-seekers: Associations with distress, depression, and disability. 
Schizophr Bull. 2006; 32(2): 352-9. 
80. Addington J, Cadenhead KS, Cannon TD, Cornblatt B, McGlashan TH, Perkins DO, et al. North 
American Prodrome Longitudinal Study: A collaborative multisite approach to prodromal schizophrenia 
research. Schizophr Bull. 2007; 33(3): 665-72. 
81. Ballon JS, Kaur T, Marks, II, Cadenhead KS. Social functioning in young people at risk for 
schizophrenia. Psychiatry Res. 2007; 151(1-2): 29-35. 
82. Berger G, Dell'Olio M, Amminger P, Cornblatt B, Phillips L, Yung A, et al. Neuroprotection in 
emerging psychotic disorders. Early Interv Psychiatry. 2007; 1(2): 114-27. 
83. Cannon TD, Cornblatt B, McGorry P. Editor's introduction: The empirical status of the ultra high-
risk (prodromal) research paradigm. Schizophr Bull. 2007; 33(3): 661-4. 
84. Cornblatt BA, Lencz T, Smith CW, Olsen R, Auther AM, Nakayama E, et al. Can antidepressants 
be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of 
adolescents. J Clin Psychiatry. 2007; 68(4): 546-57. 
85. Czernikiewicz A, Szulc A. Pre-psychotic states - contemporary diagnostic and therapeutic issues. 
Part I. Clinical identification of pre-psychotic states. Psychiatr Pol. 2007; 41(1): 5-15. 
86. Jabben N, van Os J, Janssen I, Versmissen D, Krabbendam L. Cognitive alterations in groups at 
risk for psychosis: neutral markers of genetic risk or indicators of social disability? Acta Psychiatr Scand. 
2007; 116(4): 253-62. 
87. Killackey E, Yung AR, Mc Gorry PD. Early psychosis: Where we've been, where we still have to 
go. Epidemiologia E Psichiatria Sociale-an International Journal for Epidemiology and Psychiatric 
Sciences. 2007; 16(2): 102-8. 
88. Kok ET, Groeneveld FPMJ, Busschbach JJV, Hop WCJ, Bosch JLHR, Thomas S, et al. Influence of 
coping styles on quality of life in men with new and increasing lower urinary tract symptoms. Urol Int. 
2007; 79(3): 226-30. 
89. Morrison AP, French P, Parker S, Roberts M, Stevens H, Bentall RP, et al. Three-year follow-up of 
a randomized controlled trial of cognitive therapy for the prevention of psychosis in people at ultrahigh 
risk. Schizophr Bull. 2007; 33(3): 682-7. 
90. Myles-Worsley M, Ord LM, Ngiralmau H, Weaver S, Blailes F, Faraone SV. The Palau Early 
Psychosis Study: Neurocognitive functioning in high-risk adolescents. Schizophr Res. 2007; 89(1-3): 299-
307. 
 24 
 
91. Nieman D, Becker H, van de Fliert R, Plat N, Bour L, Koelman H, et al. Antisaccade task 
performance in patients at ultra high risk for developing psychosis. Schizophr Res. 2007; 95(1-3): 54-60. 
92. Niendam TA, Horwitz J, Bearden CE, Cannon TD. Ecological assessment of executive dysfunction 
in the psychosis prodrome: A pilot study. Schizophr Res. 2007; 93(1-3): 350-4. 
93. Niendam TA, Bearden CE, Zinberg J, Johnson JK, O'Brien M, Cannon TD. The course of 
neurocognition and social functioning in individuals at ultra high risk for psychosis. Schizophr Bull. 2007; 
33(3): 772-81. 
94. Niendam TA, Zinberg J, Bearden CE, O'Brien M, Daley M, Cannon TD. Relationship between 
adolescent cognitive functioning and family environment in the psychosis prodrome. Biol Psychiatry. 
2007; 61(8): 77S-S. 
95. Patel V, Flisher AJ, Hetrick S, McGorry P. Adolescent Health 3 - Mental health of young people: a 
global public-health challenge. Lancet. 2007; 369(9569): 1302-13. 
96. Phillips LJ, McGorry PD, Yuen HP, Ward J, Donovan K, Kelly D, et al. Medium term follow-up of a 
randomized controlled trial of interventions for young people at ultra high risk of psychosis. Schizophr 
Res. 2007; 96(1-3): 25-33. 
97. Pinkham AE, Penn DL, Perkins DO, Graham KA, Siegel M. Emotion perception and social skill over 
the course of psychosis: a comparison of individuals "at-risk" for psychosis and individuals with early and 
chronic schizophrenia spectrum illness. Cogn Neuropsychiatry. 2007; 12(3): 198-212. 
98. Sanderson S, Tatt ID, Higgins JP. Tools for assessing quality and susceptibility to bias in 
observational studies in epidemiology: a systematic review and annotated bibliography. Int J Epidemiol. 
2007; 36(3): 666-76. 
99. Schultze-Lutter F, Klosterkötter J, Picker H, Steinmeyer E-M, Ruhrmann S. Predicting first-
episode psychosis by basic symptom criteria. Clin Neuropsychiatry. 2007; 4(1): 11-22. 
100. Simon AE, Cattapan-Ludewig K, Zmilacher S, Arbach D, Gruber K, Dvorsky DN, et al. Cognitive 
functioning in the schizophrenia prodrome. Schizophr Bull. 2007; 33(3): 761-71. 
101. Svirskis T, Korkeila J, Heinimaa M, Huttunen J, Ilonen T, Ristkari T, et al. Quality of life and 
functioning ability in subjects vulnerable to psychosis. Compr Psychiatry. 2007; 48(2): 155-60. 
102. Thompson KN, Phillips LJ, Komesaroff P, Yuen HP, Wood SJ, Pantelis C, et al. Stress and HPA-axis 
functioning in young people at ultra high risk for psychosis. J Psychiatr Res. 2007; 41(7): 561-9. 
103. Thompson KN, Berger G, Phillips LJ, Komesaroff P, Purcell R, McGorry PD. HPA axis functioning 
associated with transition to psychosis: Combined DEX/CRH test. J Psychiatr Res. 2007; 41(5): 446-50. 
104. Yung AR, Yuen HP, Berger G, Francey S, Hung T-C, Nelson B, et al. Declining transition rate in 
ultra high risk (prodromal) services: Dilution or reduction of risk? Schizophr Bull. 2007; 33(3): 673-81. 
105. Cannon TD, Cadenhead K, Cornblatt B, Woods SW, Addington J, Walker E, et al. Prediction of 
psychosis in youth at high clinical risk. Arch Gen Psychiatry. 2008; 65(1): 28-37. 
106. Corcoran CM, Kimhy D, Stanford A, Khan S, Walsh J, Thompson J, et al. Temporal association of 
cannabis use with symptoms in individuals at clinical high risk for psychosis. Schizophr Res. 2008; 106(2-
3): 286-93. 
107. De Masi S, Sampaolo L, Mele A, Morciano C, Cappello S, Meneghelli A, et al. The Italian 
guidelines for early intervention in schizophrenia: development and conclusions. Early Interv Psychiatry. 
2008; 2(4): 291-302. 
 25 
 
108. Hurlemann R, Jessen F, Wagner M, Frommann I, Ruhrmann S, Brockhaus A, et al. Interrelated 
neuropsychological and anatomical evidence of hippocampal pathology in the at-risk mental state. 
Psychol Med. 2008; 38(6): 843-51. 
109. Karlsgodt KH, Niendam TA, Poldrack RA, Bearden CE, Cannon TD. White matter integrity and 
prediction of social and role functioning in subjects at ultra-high risk for psychosis. Biol Psychiatry. 2008; 
63(7): 256S-S. 
110. O'Brien MP, Zinberg JL, Bearden CE, Lopez SR, Kopelowicz A, Daley M, et al. Parent attitudes and 
parent adolescent interaction in families of youth at risk for psychosis and with recent-onset psychotic 
symptoms. Early Interv Psychiatry. 2008; 2(4): 268-76. 
111. Oezguerdal S, Gudlowski Y, Witthaus H, Kawohl W, Uhl I, Hauser M, et al. Reduction of auditory 
event-related P300 amplitude in subjects with at-risk mental state for schizophrenia. Schizophr Res. 
2008; 105(1-3): 272-8. 
112. Shim G, Kang D-H, Choi J-S, Jung MH, Kwon SJ, Jang GE, et al. Prospective outcome of early 
intervention for individuals at ultra-high-risk for psychosis. Early Interv Psychiatry. 2008; 2(4): 277-84. 
113. Shim G, Kang D-H, Chung YS, Yoo SY, Shin NY, Kwon JS. Social functioning deficits in young 
people at risk for schizophrenia. Aust N Z J Psychiatry. 2008; 42(8): 678-85. 
114. Tarbox SI, Pogue-Geile MF. Development of social functioning in preschizophrenia children and 
adolescents: A systematic review. Psychol Bull. 2008; 134(4): 561-83. 
115. Willhite RK, Niendam TA, Bearden CE, Zinberg J, O'Brien MP, Cannon TD. Gender differences in 
symptoms, functioning and social support in patients at ultra-high risk for developing a psychotic 
disorder. Schizophr Res. 2008; 104(1-3): 237-45. 
116. Yung AR, Nelson B, Stanford C, Simmons MB, Cosgrave EM, Killackey E, et al. Validation of 
"prodromal" criteria to detect individuals at ultra high risk of psychosis: 2 year follow-up. Schizophr Res. 
2008; 105(1-3): 10-7. 
117. Fusar-Poli P, Meneghelli A, Valmaggia L, Allen P, Galvan F, McGuire P, et al. Duration of 
untreated prodromal symptoms and 12-month functional outcome of individuals at risk of psychosis. Br 
J Psychiatry. 2009; 194(2): 181-2. 
118. Grano N, Karjalainen M, Anto J, Itkonen A, Edlund V, Roine M. Intervention to improve level of 
overall functioning and mental condition of adolescents at high risk of developing first-episode psychosis 
in Finland. Early Interv Psychiatry. 2009; 3(2): 94-8. 
119. Hauser M, Lautenschlager M, Gudlowski Y, Oezguerdal S, Witthaus H, Bechdolf A, et al. 
Psychoeducation with patients at-risk for schizophrenia-An exploratory pilot study. Patient Educ Couns. 
2009; 76(1): 138-42. 
120. Karlsgodt KH, Niendam TA, Bearden CE, Cannon TD. White Matter Integrity and Prediction of 
Social and Role Functioning in Subjects at Ultra-High Risk for Psychosis. Biol Psychiatry. 2009; 66(6): 562-
9. 
121. Keri S, Kiss I, Kelemen O. Effects of a neuregulin 1 variant on conversion to schizophrenia and 
schizophreniform disorder in people at high risk for psychosis. Mol Psychiatry. 2009; 14(2): 118-9. 
122. Koutsouleris N, Schmitt GJE, Gaser C, Bottlender R, Scheuerecker J, McGuire P, et al. 
Neuroanatomical correlates of different vulnerability states for psychosis and their clinical outcomes. Br 
J Psychiatry. 2009; 195(3): 218-26. 
 26 
 
123. Niendam TA, Jalbrzikowski M, Bearden CE. Exploring Predictors of Outcome in the Psychosis 
Prodrome: Implications for Early Identification and Intervention. Neuropsychol Rev. 2009; 19(3): 280-93. 
124. O'Brien MP, Zinberg JL, Ho L, Rudd A, Kopelowicz A, Daley M, et al. Family problem solving 
interactions and 6-month symptomatic and functional outcomes in youth at ultra-high risk for psychosis 
and with recent onset psychotic symptoms: A longitudinal study. Schizophr Res. 2009; 107(2-3): 198-
205. 
125. Oezguerdal S, Littmann E, Hauser M, von Reventlow H, Gudlowski Y, Witthaus H, et al. 
Neurocognitive performances in participants of at-risk mental state for schizophrenia and in first-
episode patients. J Clin Exp Neuropsychol. 2009; 31(4): 392-401. 
126. Phillips LJ, Nelson B, Yuen HP, Francey SM, Simmons M, Stanford C, et al. Randomized controlled 
trial of interventions for young people at ultra-high risk of psychosis: study design and baseline 
characteristics. Aust N Z J Psychiatry. 2009; 43(9): 818-29. 
127. Riecher-Roessler A, Pflueger MO, Aston J, Borgwardt SJ, Brewer WJ, Gschwandtner U, et al. 
Efficacy of Using Cognitive Status in Predicting Psychosis: A 7-Year Follow-Up. Biol Psychiatry. 2009; 
66(11): 1023-30. 
128. Simon AE, Cattapan-Ludewig K, Gruber K, Ouertani J, Zimmer A, Roth B, et al. Subclinical 
hallucinations in adolescent outpatients: An outcome study. Schizophr Res. 2009; 108(1-3): 265-71. 
129. Velthorst E, Nieman DH, Becker HE, van de Fliert R, Dingemans PM, Klaassen R, et al. Baseline 
differences in clinical symptomatology between ultra high risk subjects with and without a transition to 
psychosis. Schizophr Res. 2009; 109(1-3): 60-5. 
130. Yung AR, Nelson B, Baker K, Buckby JA, Baksheev G, Cosgrave EM. Psychotic-like experiences in a 
community sample of adolescents: implications for the continuum model of psychosis and prediction of 
schizophrenia. Aust N Z J Psychiatry. 2009; 43(2): 118-28. 
131. Amminger GP, Schafer MR, Papageorgiou K, Klier CM, Cotton SM, Harrigan SM, et al. Long-Chain 
omega-3 Fatty Acids for Indicated Prevention of Psychotic Disorders A Randomized, Placebo-Controlled 
Trial. Arch Gen Psychiatry. 2010; 67(2): 146-54. 
132. Armando M, Nelson B, Yung AR, Ross M, Birchwood M, Girardi P, et al. Psychotic-like 
experiences and correlation with distress and depressive symptoms in a community sample of 
adolescents and young adults. Schizophr Res. 2010; 119(1-3): 258-65. 
133. Chung Y-C, Jung H-Y, Kim S-W, Lee S-H, Shin S-E, Shin Y-M, et al. What factors are related to 
delayed treatment in individuals at high risk for psychosis? Early Interv Psychiatry. 2010; 4(2): 124-31. 
134. Compton MT, Goulding SM, Walker EF. Characteristics of the Retrospectively Assessed 
Prodromal Period in Hospitalized Patients With First-Episode Nonaffective Psychosis: Findings From a 
Socially Disadvantaged, Low-Income, Predominantly African American Population. J Clin Psychiatry. 
2010; 71(10): 1279-85. 
135. Fusar-Poli P, Broome MR, Matthiasson P, Woolley JB, Johns LC, Tabraham P, et al. Spatial 
working memory in individuals at high risk for psychosis: Longitudinal fMRI study. Schizophr Res. 2010; 
123(1): 45-52. 
136. Fusar-Poli P, Byrne M, Valmaggia L, Day F, Tabraham P, Johns L, et al. Social dysfunction predicts 
two years clinical outcome in people at ultra high risk for psychosis. J Psychiatr Res. 2010; 44(5): 294-
301. 
 27 
 
137. Ilonen T, Heinimaa M, Korkeila J, Svirskis T, Salokangas RKR. Differentiating adolescents at 
clinical high risk for psychosis from psychotic and non-psychotic patients with the Rorschach. Psychiatry 
Res. 2010; 179(2): 151-6. 
138. Jang JH, Hur JW, Shim G, Kwon SJ, Park HY, Kim E, et al. Change in social functioning in 
individuals at ultra-high-risk for psychosis: 1-year longitudinal study. Int J Neuropsychopharmacol. 2010; 
13: 222-. 
139. Korver N, Nieman DH, Becker HE, van de Fliert JR, Dingemans PH, de Haan L, et al. 
Symptomatology and neuropsychological functioning in cannabis using subjects at ultra-high risk for 
developing psychosis and healthy controls. Aust N Z J Psychiatry. 2010; 44(3): 230-6. 
140. Koutsouleris N, Patschurek-Kliche K, Scheuerecker J, Decker P, Bottlender R, Schmitt G, et al. 
Neuroanatomical correlates of executive dysfunction in the at-risk mental state for psychosis. Schizophr 
Res. 2010; 123(2-3): 160-74. 
141. Linszen D, Korver N, Nieman D, Becker H, van de Fliert J, Dingemans P, et al. Symptomatology 
and neuropsychological functioning in cannabis using subjects at ultra high risk for developing psychosis 
and healthy controls. Schizophr Res. 2010; 117(2-3): 164-5. 
142. Luebbe AM, Bell DJ, Allwood MA, Swenson LP, Early MC. Social Information Processing in 
Children: Specific Relations to Anxiety, Depression, and Affect. J Clin Child Adolesc Psychol. 2010; 39(3): 
386-99. 
143. Machielsen M, van der Sluis S, de Haan L. Cannabis use in patients with a first psychotic episode 
and subjects at ultra high risk of psychosis: impact on psychotic and pre-psychotic symptoms. Aust N Z J 
Psychiatry. 2010; 44(8): 721-8. 
144. Mittal VA, Walker EF, Bearden CE, Walder D, Trottman H, Daley M, et al. Markers of Basal 
Ganglia Dysfunction and Conversion to Psychosis: Neurocognitive Deficits and Dyskinesias in the 
Prodromal Period. Biol Psychiatry. 2010; 68(1): 93-9. 
145. Nelson B, Yung AR. Can clinicians predict psychosis in an ultra high risk group? Aust N Z J 
Psychiatry. 2010; 44(7): 625-30. 
146. Romano DM, McCay E, Goering P, Boydell K, Zipursky R. Treatment history in the psychosis 
prodrome: characteristics of the North American Prodrome Longitudinal Study Cohort. Early Interv 
Psychiatry. 2010; 4(3): 243-50. 
147. Ruhrmann S, Schultze-Lutter F, Klosterkoetter J. Probably at-risk, but certainly ill - Advocating 
the introduction of a psychosis spectrum disorder in DSM-V. Schizophr Res. 2010; 120(1-3): 23-37. 
148. Ruhrmann S, Schultze-Lutter F, Salokangas RKR, Heinimaa M, Linszen D, Dingemans P, et al. 
Prediction of Psychosis in Adolescents and Young Adults at High Risk Results From the Prospective 
European Prediction of Psychosis Study. Arch Gen Psychiatry. 2010; 67(3): 241-51. 
149. Sabb FW, van Erp TGM, Hardt ME, Dapretto M, Caplan R, Cannon TD, et al. Language network 
dysfunction as a predictor of outcome in youth at clinical high risk for psychosis. Schizophr Res. 2010; 
116(2-3): 173-83. 
150. Schlosser DA, Zinberg JL, Loewy RL, Casey-Cannon S, O'Brien MP, Bearden CE, et al. Predicting 
the longitudinal effects of the family environment on prodromal symptoms and functioning in patients 
at-risk for psychosis. Schizophr Res. 2010; 118(1-3): 69-75. 
 28 
 
151. Seidman LJ, Giuliano AJ, Meyer EC, Addington J, Cadenhead KS, Cannon TD, et al. 
Neuropsychology of the Prodrome to Psychosis in the NAPLS Consortium Relationship to Family History 
and Conversion to Psychosis. Arch Gen Psychiatry. 2010; 67(6): 578-88. 
152. Shim G, Oh JS, Jung WH, Jang JH, Choi C-H, Kim E, et al. Altered resting-state connectivity in 
subjects at ultra-high risk for psychosis: an fMRI study. Behavioral and Brain Functions. 2010; 6. 
153. Simon AE, Umbricht D. High remission rates from an initial ultra-high risk state for psychosis. 
Schizophr Res. 2010; 116(2-3): 168-72. 
154. Velthorst E, Nieman DH, Linszen D, Becker H, de Haan L, Dingemans PM, et al. Disability in 
people clinically at high risk of psychosis. Br J Psychiatry. 2010; 197(4): 278-84. 
155. Woodberry KA, Seidman LJ, Giuliano AJ, Verdi MB, Cook WL, McFarlane WR. Neuropsychological 
profiles in individuals at clinical high risk for psychosis: Relationship to psychosis and intelligence. 
Schizophr Res. 2010; 123(2-3): 188-98. 
156. Addington J, Cornblatt BA, Cadenhead KS, Cannon TD, McGlashan TH, Perkins DO, et al. At 
Clinical High Risk for Psychosis: Outcome for Nonconverters. Am J Psychiatry. 2011; 168(8): 800-5. 
157. Addington J, Epstein I, Liu L, French P, Boydell KM, Zipursky RB. A randomized controlled trial of 
cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophr Res. 2011; 125(1): 
54-61. 
158. Bechdolf A, Mueller H, Stuetzer H, Wagner M, Maier W, Lautenschlager M, et al. Rationale and 
Baseline Characteristics of PREVENT: A Second-Generation Intervention Trial in Subjects At-Risk 
(Prodromal) of Developing First-Episode Psychosis Evaluating Cognitive Behavior Therapy, Aripiprazole, 
and Placebo for the Prevention of Psychosis. Schizophr Bull. 2011; 37: S111-S21. 
159. Bruene M, Oezguerdal S, Ansorge N, von Reventlow HG, Peters S, Nicolas V, et al. An fMRI study 
of "theory of mind" in at-risk states of psychosis: Comparison with manifest schizophrenia and healthy 
controls. Neuroimage. 2011; 55(1): 329-37. 
160. Collip D, Nicolson NA, Lardinois M, Lataster T, van Os J, Myin-Germeys I, et al. Daily cortisol, 
stress reactivity and psychotic experiences in individuals at above average genetic risk for psychosis. 
Psychol Med. 2011; 41(11): 2305-15. 
161. Corcoran CM, Kimhy D, Parrilla-Escobar MA, Cressman VL, Stanford AD, Thompson J, et al. The 
relationship of social function to depressive and negative symptoms in individuals at clinical high risk for 
psychosis. Psychol Med. 2011; 41(2): 251-61. 
162. Fontenelle LF, Lin A, Pantelis C, Wood SJ, Nelson B, Yung AR. A longitudinal study of obsessive-
compulsive disorder in individuals at ultra-high risk for psychosis. J Psychiatr Res. 2011; 45(9): 1140-5. 
163. Frommann I, Pukrop R, Brinkmeyer J, Bechdolf A, Ruhrmann S, Berning J, et al. 
Neuropsychological Profiles in Different At-Risk States of Psychosis: Executive Control Impairment in the 
Early-and Additional Memory Dysfunction in the Late-Prodromal State. Schizophr Bull. 2011; 37(4): 861-
73. 
164. Fusar-Poli P, Broome MR, Woolley JB, Johns LC, Tabraham P, Bramon E, et al. Altered brain 
function directly related to structural abnormalities in people at ultra high risk of psychosis: longitudinal 
VBM-fMRI study. J Psychiatr Res. 2011; 45(2): 190-8. 
165. Fusar-Poli P, Broome MR, Matthiasson P, Woolley JB, Mechelli A, Johns LC, et al. Prefrontal 
Function at Presentation Directly Related to Clinical Outcome in People at Ultrahigh Risk of Psychosis. 
Schizophr Bull. 2011; 37(1): 189-98. 
 29 
 
166. Gee DG, Cannon TD. Prediction of conversion to psychosis: review and future directions. Revista 
brasileira de psiquiatria (Sao Paulo, Brazil: 1999). 2011; 33 Suppl 2: s129-42. 
167. Grano N, Karjalainen M, Anto J, Itkonen A, Edlund V, Roine M. Associations between number of 
different type of care meetings with social network and improvement in mental well-being in 
adolescents at risk of first-episode psychosis. Early Interv Psychiatry. 2011; 5(3): 212-8. 
168. Grano N, Karjalainen M, Suominen K, Roine M. Poor functioning ability is associated with high 
risk of developing psychosis in adolescents. Nord J Psychiatry. 2011; 65(1): 16-21. 
169. Jang JH, Shin NY, Shim G, Park HY, Kim E, Jang G-E, et al. Longitudinal patterns of social 
functioning and conversion to psychosis in subjects at ultra-high risk. Aust N Z J Psychiatry. 2011; 45(9): 
763-70. 
170. Keshavan MS, DeLisi LE, Seidman LJ. Early and broadly defined psychosis risk mental states. 
Schizophr Res. 2011; 126(1-3): 1-10. 
171. Lin A, Wood SJ, Nelson B, Brewer WJ, Spiliotacopoulos D, Bruxner A, et al. Neurocognitive 
predictors of functional outcome two to 13 years after identification as ultra-high risk for psychosis. 
Schizophr Res. 2011; 132(1): 1-7. 
172. Mees L, Zdanowicz N, Reynaert C, Jacques D. Adolescents and young adults at ultrahigh risk of 
psychosis: detection, prediction and treatment. A review of current knowledge. Psychiatria Danubina. 
2011; 23: S118-S22. 
173. Mittal VA, Jalbrzikowski M, Daley M, Roman C, Bearden CE, Cannon TD. Abnormal movements 
are associated with poor psychosocial functioning in adolescents at high risk for psychosis. Schizophr 
Res. 2011; 130(1-3): 164-9. 
174. Mukkala S, Ilonen T, Nordstrom T, Miettunen J, Loukkola J, Barnett JH, et al. Different 
vulnerability indicators for psychosis and their neuropsychological characteristics in the Northern 
Finland 1986 Birth Cohort. J Clin Exp Neuropsychol. 2011; 33(4): 385-94. 
175. Niendam TA, Ragland JD, Dean YM, Westphal AJ, Auther A, Cornblatt BA, et al. Impaired 
Prefrontal Functioning as a Marker of Psychosis Risk State. Schizophr Bull. 2011; 37: 222-. 
176. Raballo A, Nelson B, Thompson A, Yung A. The Comprehensive Assessment of At-Risk Mental 
States: From mapping the onset to mapping the structure. Schizophr Res. 2011; 127(1-3): 107-14. 
177. Rauchensteiner S, Kawohl W, Ozgurdal S, Littmann E, Gudlowski Y, Witthaus H, et al. Test-
performance after cognitive training in persons at risk mental state of schizophrenia and patients with 
schizophrenia. Psychiatry Res. 2011; 185(3): 334-9. 
178. Rietdijk J, Hogerzeil SJ, van Hemert AM, Cuijpers P, Linszen DH, van der Gaag M. Pathways to 
psychosis: Help-seeking behavior in the prodromal phase. Schizophr Res. 2011; 132(2-3): 213-9. 
179. Simeonova DI, Attalla A, Trotman H, Esterberg M, Walker EF. Does a parent-report measure of 
behavioral problems enhance prediction of conversion to psychosis in clinical high-risk adolescents? 
Schizophr Res. 2011; 130(1-3): 157-63. 
180. Song YY, Kim KR, Park JY, Lee SY, Kang JI, Lee E, et al. Associated factors of quality of life in first-
episode schizophrenia patients. Psychiatry Investig. 2011; 8(3): 201-6. 
181. van Rijn S, Schothorst P, van 't Wout M, Sprong M, Ziermans T, van Engeland H, et al. Affective 
dysfunctions in adolescents at risk for psychosis: Emotion awareness and social functioning. Psychiatry 
Res. 2011; 187(1-2): 100-5. 
 30 
 
182. Velthorst E, Nieman DH, Klaassen RMC, Becker HE, Dingemans PM, Linszen DH, et al. Three-year 
course of clinical symptomatology in young people at ultra high risk for transition to psychosis. Acta 
Psychiatr Scand. 2011; 123(1): 36-42. 
183. Yung AR, Phillips LJ, Nelson B, Francey SM, PanYuen H, Simmons MB, et al. Randomized 
Controlled Trial of Interventions for Young People at Ultra High Risk for Psychosis: 6-Month Analysis. J 
Clin Psychiatry. 2011; 72(4): 430-40. 
184. Addington J, Barbato M. The role of cognitive functioning in the outcome of those at clinical high 
risk for developing psychosis. Epidemiology and Psychiatric Sciences. 2012; 21(4): 335-42. 
185. Amminger GP, Schaefer MR, Klier CM, Schloegelhofer M, Mossaheb N, Thompson A, et al. Facial 
and vocal affect perception in people at ultra-high risk of psychosis, first-episode schizophrenia and 
healthy controls. Early Interv Psychiatry. 2012; 6(4): 450-4. 
186. Armando M, Vicari S, Girardi P, Pontillo M, Saba R, Lin A, et al. A comparison of general 
functioning and prodromal positive and negative psychotic symptoms between adolescents at clinical 
ultra high risk with and without 22Q11 deletion syndrome. Early Interv Psychiatry. 2012; 6: 40-. 
187. Armando M, Girardi P, Vicari S, Menghini D, Digilio MC, Pontillo M, et al. Adolescents at ultra-
high risk for psychosis with and without 22q11 deletion syndrome: A comparison of prodromal psychotic 
symptoms and general functioning. Schizophr Res. 2012; 139(1-3): 151-6. 
188. Bechdolf A, Wagner M, Ruhrmann S, Harrigan S, Putzfeld V, Pukrop R, et al. Preventing 
progression to first-episode psychosis in early initial prodromal states. Br J Psychiatry. 2012; 200(1): 22-
9. 
189. Bowie CR, McLaughlin D, Carrion RE, Auther AM, Cornblatt BA. Cognitive changes following 
antidepressant or antipsychotic treatment in adolescents at clinical risk for psychosis. Schizophr Res. 
2012; 137(1-3): 110-7. 
190. Cornblatt BA, Carrion RE, Addington J, Seidman L, Walker EF, Cannon TD, et al. Risk factors for 
psychosis: impaired social and role functioning. Schizophr Bull. 2012; 38(6): 1247-57. 
191. Demjaha A, Valmaggia L, Stahl D, Byrne M, McGuire P. Disorganization/Cognitive and Negative 
Symptom Dimensions in the At-Risk Mental State Predict Subsequent Transition to Psychosis. Schizophr 
Bull. 2012; 38(2): 351-9. 
192. Fusar-Poli P, Deste G, Smieskova R, Barlati S, Yung AR, Howes O, et al. Cognitive Functioning in 
Prodromal Psychosis A Meta-analysis. Arch Gen Psychiatry. 2012; 69(6): 562-71. 
193. Fusar-Poli P, Bonoldi I, Yung AR, Borgwardt S, Kempton MJ, Valmaggia L, et al. Predicting 
psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry. 
2012; 69(3): 220-9. 
194. Hur J-W, Shin NY, Jang JH, Shim G, Park HY, Hwang JY, et al. Clinical and neurocognitive profiles 
of subjects at high risk for psychosis with and without obsessive-compulsive symptoms. Aust N Z J 
Psychiatry. 2012; 46(2): 161-9. 
195. Jaracz J, Grzechowiak M, Raczkowiak L, Rataj K, Rybakowski J. Polish version of Comprehensive 
Assessment of At Risk Mental States (CAARMS) - the description of the method. Psychiatr Pol. 2012; 
46(1): 95-107. 
196. Kelleher I, Murtagh A, Molloy C, Roddy S, Clarke MC, Harley M, et al. Identification and 
Characterization of Prodromal Risk Syndromes in Young Adolescents in the Community: A Population-
Based Clinical Interview Study. Schizophr Bull. 2012; 38(2): 239-46. 
 31 
 
197. Lavoie S, Schaefer MR, Whitford TJ, Benninger F, Feucht M, Klier CM, et al. Frontal delta power 
associated with negative symptoms in ultra-high risk individuals who transitioned to psychosis. 
Schizophr Res. 2012; 138(2-3): 206-11. 
198. Lee DY, Smith GN, Su W, Honer WG, MacEwan GW, Lapointe JS, et al. White matter tract 
abnormalities in first-episode psychosis. Schizophr Res. 2012; 141(1): 29-34. 
199. Lin A, Nelson B, Yung AR. 'At-risk' for psychosis research: where are we heading? Epidemiology 
and Psychiatric Sciences. 2012; 21(4): 329-34. 
200. Marques TR, Smith S, Bonaccorso S, Gaughran F, Kolliakou A, Dazzan P, et al. Sexual dysfunction 
in people with prodromal or first-episode psychosis. Br J Psychiatry. 2012; 201(2): 131-6. 
201. Marshall C, Addington J, Epstein I, Liu L, Deighton S, Zipursky RB. Treating young individuals at 
clinical high risk for psychosis. Early Interv Psychiatry. 2012; 6(1): 60-8. 
202. Masillo A, Day F, Laing J, Howes O, Fusar-Poli P, Byrne M, et al. Interpersonal sensitivity in the 
at-risk mental state for psychosis. Psychol Med. 2012; 42(9): 1835-45. 
203. Morrison AP, French P, Stewart SLK, Birchwood M, Fowler D, Gumley AI, et al. Early detection 
and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial. Br Med 
J. 2012; 344. 
204. Quijada Y, Tizon JL, Artigue J, Kwapil TR, Barrantes-Vidal N. Attachment style predicts 6-month 
improvement in psychoticism in persons with at-risk mental states for psychosis. Early Interv Psychiatry. 
2012; 6(4): 442-9. 
205. Rao S, Poon LY, Verma S, Tay SA, Yuen S, Lim LK, et al. Prevalence and functioning in patients 
with at risk mental state and comorbid psychiatric disorders. Early Interv Psychiatry. 2012; 6: 120-. 
206. Remberk B, Namyslowska I, Rybakowski F. Cognition and communication dysfunctions in early-
onset schizophrenia: Effect of risperidone. Prog Neuropsychopharmacol Biol Psychiatry. 2012; 39(2): 
348-54. 
207. Rietdijk J, Klaassen R, Ising H, Dragt S, Nieman DH, van de Kamp J, et al. Detection of people at 
risk of developing a first psychosis: comparison of two recruitment strategies. Acta Psychiatr Scand. 
2012; 126(1): 21-30. 
208. Schultze-Lutter F, Klosterkoetter J, Michel C, Winkler K, Ruhrmann S. Personality disorders and 
accentuations in at-risk persons with and without conversion to first-episode psychosis. Early Interv 
Psychiatry. 2012; 6(4): 389-98. 
209. Song YY, Kim KR, Lee EH, Park JY, Kang JI, Lee E, et al. Associated factors of quality of life in ultra-
high risk for psychosis. Early Interv Psychiatry. 2012; 6: 126-. 
210. Stain H, Paulik G, Atkinson R, Carr V, Curtis J, Ehlkes T, et al. Clinical, social and neurocognitive 
functioning in youth at ultra high risk for psychosis: Baseline findings from the Minds in Transition 
(MINT) longitudinal cohort. Early Interv Psychiatry. 2012; 6: 118-. 
211. Strobl EV, Eack SM, Swaminathan V, Visweswaran S. Predicting the risk of psychosis onset: 
advances and prospects. Early Interv Psychiatry. 2012; 6(4): 368-79. 
212. Tomassini A, Roncone R, Verni L, Ortenzi R, Di Melchiorre G, Tosone A, et al. Use of cannabis and 
psychopathological risk in onset psychosis. Rivista Di Psichiatria. 2012; 47(2): 170-7. 
 32 
 
213. Valli I, Tognin S, Fusar-Poli P, Mechelli A. Episodic Memory Dysfunction in Individuals at High-
Risk of Psychosis: A Systematic Review of Neuropsychological and Neurofunctional Studies. Curr Pharm 
Des. 2012; 18(4): 443-58. 
214. van der Gaag M, Nieman DH, Rietdijk J, Dragt S, Ising HK, Klaassen RMC, et al. Cognitive 
Behavioral Therapy for Subjects at Ultrahigh Risk for Developing Psychosis: A Randomized Controlled 
Clinical Trial. Schizophr Bull. 2012; 38(6): 1180-8. 
215. Verma S, Poon LY, Lee H, Rao S, Chong SA. Evolution of early psychosis intervention services in 
Singapore. East Asian archives of psychiatry : official journal of the Hong Kong College of Psychiatrists = 
Dong Ya jing shen ke xue zhi : Xianggang jing shen ke yi xue yuan qi kan. 2012; 22(3): 114-7. 
216. Addington J, Stowkowy J, Cadenhead KS, Cornblatt BA, McGlashan TH, Perkins DO, et al. Early 
traumatic experiences in those at clinical high risk for psychosis. Early Interv Psychiatry. 2013; 7(3): 300-
5. 
217. Amminger GP, Chanen AM, Ohmann S, Klier CM, Mossaheb N, Bechdolf A, et al. Omega-3 fatty 
acid supplementation in adolescents with borderline personality disorder and ultra-high risk criteria for 
psychosis: a post hoc subgroup analysis of a double-blind, randomized controlled trial. Can J Psychiatry. 
2013; 58(7): 402-8. 
218. Bugra H, Studerus E, Rapp C, Tamagni C, Aston J, Borgwardt S, et al. Cannabis use and cognitive 
functions in at-risk mental state and first episode psychosis. Psychopharmacology (Berl). 2013; 230(2): 
299-308. 
219. Comparelli A, Pucci D, Savoja V, Kotzalidis GD, Falcone I, Angelone M, et al. Mental disorders 
diagnosed in childhood and at-risk mental state in a help-seeking population. Early Interv Psychiatry. 
2013; 7(2): 187-92. 
220. De Herdt A, Wampers M, Vancampfort D, De Hert M, Vanhees L, Demunter H, et al. 
Neurocognition in clinical high risk young adults who did or did not convert to a first schizophrenic 
psychosis: A meta-analysis. Schizophr Res. 2013; 149(1-3): 48-55. 
221. Debbane M, Badoud D, Balanzin D, Eliez S. Broadly defined risk mental states during 
adolescence: Disorganization mediates positive schizotypal expression. Schizophr Res. 2013; 147(1): 153-
6. 
222. Fusar-Poli P, Byrne M, Badger S, Valmaggia LR, McGuire PK. Outreach and support in South 
London (OASIS), 2001-2011: Ten years of early diagnosis and treatment for young individuals at high 
clinical risk for psychosis. Eur Psychiatry. 2013; 28(5): 315-26. 
223. Gerlinger G, Hauser M, De Hert M, Lacluyse K, Wampers M, Correll CU. Personal stigma in 
schizophrenia spectrum disorders: a systematic review of prevalence rates, correlates, impact and 
interventions. World Psychiatry. 2013; 12(2): 155-64. 
224. Grano N, Karjalainen M, Edlund V, Saari E, Itkonen A, Anto J, et al. Adolescents at risk of 
psychosis have higher level of hopelessness than adolescents not at risk of psychosis. Nordic Journal of 
Psychiatry. 2013; 67(4): 258-64. 
225. Hur J-W, Byun MS, Shin NY, Shin YS, Kim SN, Jang JH, et al. General intellectual functioning as a 
buffer against theory-of-mind deficits in individuals at ultra-high risk for psychosis. Schizophr Res. 2013; 
149(1-3): 83-7. 
 33 
 
226. Jalbrzikowski M, Krasileva KE, Marvin S, Zinberg J, Andaya A, Bachman P, et al. Reciprocal social 
behavior in youths with psychotic illness and those at clinical high risk. Dev Psychopathol. 2013; 25(4 Pt 
1): 1187-97. 
227. Kelleher I, Murtagh A, Clarke MC, Murphy J, Rawdon C, Cannon M. Neurocognitive performance 
of a community-based sample of young people at putative ultra high risk for psychosis: Support for the 
processing speed hypothesis. Cogn Neuropsychiatry. 2013; 18(1-2): 9-25. 
228. Kline E, Thompson E, Schimunek C, Reeves G, Bussell K, Pitts SC, et al. Parent-adolescent 
agreement on psychosis risk symptoms. Schizophr Res. 2013; 147(1): 147-52. 
229. Lecardeur L. Cognitive behavior therapy after first-episodes psychosis. L'Encephale. 2013; 39 
Suppl 2: S115-20. 
230. Lee J, Rekhi G, Mitter N, Bong YL, Kraus MS, Lam M, et al. The Longitudinal Youth at Risk Study 
(LYRIKS) - An Asian UHR perspective. Schizophr Res. 2013; 151(1-3): 279-83. 
231. Lin A, Wood SJ, Yung AR. Measuring psychosocial outcome is good. Current Opinion in 
Psychiatry. 2013; 26(2): 138-43. 
232. Lin A, Wigman JTW, Nelson B, Wood SJ, Vollebergh WAM, van Os J, et al. Follow-up factor 
structure of schizotypy and its clinical associations in a help-seeking sample meeting ultra-high risk for 
psychosis criteria at baseline. Compr Psychiatry. 2013; 54(2): 173-80. 
233. McGorry PD, Nelson B, Phillips LJ, Yuen HP, Francey SM, Thampi A, et al. Randomized Controlled 
Trial of Interventions for Young People at Ultra-High Risk of Psychosis: Twelve-Month Outcome. J Clin 
Psychiatry. 2013; 74(4): 349-56. 
234. Mossaheb N, Schaefer MR, Schloegelhofer M, Klier CM, Cotton SM, McGorry PD, et al. Effect of 
omega-3 fatty acids for indicated prevention of young patients at risk for psychosis: When do they begin 
to be effective? Schizophr Res. 2013; 148(1-3): 163-7. 
235. Mueller H, Bechdolf A. Psychological interventions in people at-risk for first episode psychosis. 
Psychotherapeut. 2013; 58(4): 344-51. 
236. Nelson B, Yuen HP, Wood SJ, Lin A, Spiliotacopoulos D, Bruxner A, et al. Long-term Follow-up of 
a Group at Ultra High Risk ("Prodromal") for Psychosis The PACE 400 Study. JAMA Psychiatry. 2013; 
70(8): 793-802. 
237. Nieman DH, Velthorst E, Becker HE, de Haan L, Dingemans PM, Linszen DH, et al. The Strauss 
and Carpenter Prognostic Scale in subjects clinically at high risk of psychosis. Acta Psychiatr Scand. 2013; 
127(1): 53-61. 
238. Niendam TA, Ragland JD, Floyd E, Auther A, Cornblatt B, Adelsheim S, et al. Multi-Site 
Investigation of Impaired Prefrontal Functioning as a Potential Marker of Long-Term Outcome in 
Psychosis Risk State. Biol Psychiatry. 2013; 73(9): 273s-s. 
239. Rapp C, Studerus E, Bugra H, Aston J, Tamagni C, Walter A, et al. Duration of untreated psychosis 
and cognitive functioning. Schizophr Res. 2013; 145(1-3): 43-9. 
240. Ratheesh A, Lin A, Nelson B, Wood SJ, Brewer W, Betts J, et al. Neurocognitive functioning in the 
prodrome of mania-an exploratory study. J Affect Disord. 2013; 147(1-3): 441-5. 
241. Riecher-Roessler A, Aston J, Borgwardt S, Bugra H, Fuhr P, Gschwandtner U, et al. Prediction of 
Psychosis by Stepwise Multilevel Assessment - The Basel FePsy (Early Recognition of Psychosis)-Project. 
Fortschritte Der Neurologie Psychiatrie. 2013; 85(1): 265-75. 
 34 
 
242. Stafford MR, Jackson H, Mayo-Wilson E, Morrison AP, Kendall T. Early interventions to prevent 
psychosis: systematic review and meta-analysis. Bmj. 2013; 346: f185. 
243. Stowkowy J, Addington J. Predictors of a clinical high risk status among individuals with a family 
history of psychosis. Schizophr Res. 2013; 147(2-3): 281-6. 
244. Sullivan S, Herzig D, Mohr C, Lewis G, Corcoran R, Drake R, et al. Theory of mind and social 
functioning in first episode psychosis. Cogn Neuropsychiatry. 2013; 18(3): 219-42. 
245. Taylor HE, Parker S, Mansell W, Morrison AP. Effects of Appraisals of Anomalous Experience on 
Distress in People at Risk of Psychosis. Behav Cogn Psychother. 2013; 41(1): 24-33. 
246. Teyssier JR. Prodromes of schizophrenia: Consensus or confusion? Encephale-Revue De 
Psychiatrie Clinique Biologique Et Therapeutique. 2013; 39: S1-S7. 
247. Thompson A, Papas A, Bartholomeusz C, Nelson B, Yung A. Externalized attributional bias in the 
Ultra High Risk (UHR) for psychosis population. Psychiatry Res. 2013; 206(2-3): 200-5. 
248. Tiffin PA, Welsh P. Practitioner Review: Schizophrenia spectrum disorders and the at-risk mental 
state for psychosis in children and adolescents - evidence-based management approaches. Journal of 
child psychology and psychiatry, and allied disciplines. 2013; 54(11): 1155-75. 
249. Tikka M, Luutonen S, Ilonen T, Tuominen L, Kotimaki M, Hankala J, et al. Childhood trauma and 
premorbid adjustment among individuals at clinical high risk for psychosis and normal control subjects. 
Early Interv Psychiatry. 2013; 7(1): 51-7. 
250. Valmaggia LR, Stahl D, Yung AR, Nelson B, Fusar-Poli P, McGorry PD, et al. Negative psychotic 
symptoms and impaired role functioning predict transition outcomes in the at-risk mental state: a latent 
class cluster analysis study. Psychol Med. 2013; 43(11): 2311-25. 
251. Velthorst E, Nelson B, Wiltink S, de Haan L, Wood SJ, Lin A, et al. Transition to first episode 
psychosis in ultra high risk populations: Does baseline functioning hold the key? Schizophr Res. 2013; 
143(1): 132-7. 
252. Walder DJ, Holtzman CW, Addington J, Cadenhead K, Tsuang M, Cornblatt B, et al. Sexual 
dimorphisms and prediction of conversion in the NAPLS psychosis prodrome. Schizophr Res. 2013; 
144(1-3): 43-50. 
253. Zaytseva Y, Korsakova N, Agius M, Gurovich I. Neurocognitive Functioning in Schizophrenia and 
during the Early Phases of Psychosis: Targeting Cognitive Remediation Interventions. Biomed Res Intern. 
2013. 
 
10.1192/bjp.bp.114.157115Access the most recent version at DOI: 
2015, 207:198-206.BJP 
Caverzasi, Pierluigi Politi, Stephan Ruhrmann and Philip McGuire
Paolo Fusar-Poli, Matteo Rocchetti, Alberto Sardella, Alessia Avila, Martina Brandizzi, Edgardo
quality of life in people at high risk of psychosis
Disorder, not just state of risk: meta-analysis of functioning and
Material
Supplementary
http://bjp.rcpsych.org/content/suppl/2015/09/10/207.3.198.DC1
Supplementary material can be found at: 
References
http://bjp.rcpsych.org/content/207/3/198#BIBL
This article cites 86 articles, 17 of which you can access for free at: 
permissions
Reprints/
permissions@rcpsych.ac.ukwrite to 
To obtain reprints or permission to reproduce material from this paper, please
to this article at
You can respond /letters/submit/bjprcpsych;207/3/198
from 
Downloaded
The Royal College of PsychiatristsPublished by 
 on February 8, 2017http://bjp.rcpsych.org/
http://bjp.rcpsych.org/site/subscriptions/
 go to: The British Journal of PsychiatryTo subscribe to 
